Isolation of Circulating Tumor Cells and Clusters from Blood with Application in Drug Screening by Shi, Wentao
Lehigh University
Lehigh Preserve
Theses and Dissertations
2018
Isolation of Circulating Tumor Cells and Clusters
from Blood with Application in Drug Screening
Wentao Shi
Lehigh University
Follow this and additional works at: https://preserve.lehigh.edu/etd
Part of the Biomedical Engineering and Bioengineering Commons
This Dissertation is brought to you for free and open access by Lehigh Preserve. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Shi, Wentao, "Isolation of Circulating Tumor Cells and Clusters from Blood with Application in Drug Screening" (2018). Theses and
Dissertations. 4250.
https://preserve.lehigh.edu/etd/4250
Isolation of Circulating Tumor Cells and Clusters 
from Blood with Application in Drug Screening 
by 
Wentao Shi 
 
A Dissertation 
Presented to the Graduate and Research Committee 
of Lehigh University 
in Candidacy for the Degree of 
Doctor of Philosophy 
in 
Bioengineering 
Lehigh University 
May 2018 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by Wentao Shi 
 
2018 
 
 
 
 
 
 
iii 
 
Approved and recommended for acceptance as a dissertation in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in Bioengineering. 
Student: Wentao Shi 
Dissertation Title: Isolation of Circulating Tumor Cells and Clusters from Blood with 
Application in Drug Screening 
 
                                              
Date 
 
                                                                                                                                              
    Yaling Liu, Dissertation Advisor and Committee Chairman 
       
                                               
Accepted Date 
 
Committee Members: 
 
 
                                               
Chao Zhou 
 
 
                                               
Lesley Chow 
 
 
                                               
Sabrina Jedlicka 
iv 
 
Acknowledgement 
The road to my PhD degree was rough, which started from very poor oral English ability, 
zero biology background, and never-touched first projects; the road was also smooth, 
which ends with a blissful 3-member family, a few fruitful research results, and a desirable 
job offer; the road was also full of pleasure, on which I received sufficient supports from 
professors, peer friends and my family. 
First and foremost, I would like to give my sincere gratitude to my advisor, Prof. Yaling 
Liu. It was Prof. Yaling Liu who provided me the chance to study abroad and experience 
such a meaningful and fruitful journey at such a beautiful and prestigious university. He 
set high standards on me while allowed for lots of freedom on the project selection to 
emphasize my strength. I was also always inspired by his accurate foresight on searching 
for topics which was not only scientifically comprehensive, but practically meaningful. I 
would like to thank again for his endless and continuous supports on my career. 
Besides my advisor, I would like to thank the rest of my dissertation committee: Prof. Chao 
Zhou, Prof. Lesley Chow, and Prof. Sabrina Jedlicka, for their insightful comments and 
encouragement, but also for the hard question which incented me to widen my research 
from various perspectives. My special thanks go to Prof. Chao Zhou who guided me 
through a couple projects. And another great thanks also go to Prof. Susan Perry, who 
always provided useful information when I needed. 
To my peer colleagues and friends at Lehigh University, I really enjoyed the time 
to be together with you and will never forget it. Thanks for the tremendous happiness 
brought by a group of Chinese male labmates including Dr. Jifu Tan, Dr. Ran He and Dr. 
Shunqiang Wang. I will miss the time with you together forever. Special thanks to Dr. Ran 
He: working with you was full of challenge but meaningful and funny. Another special 
thanks to Christopher Uhl, who always held wide science background and provided 
meaningful suggestions to all my projects. Also thanks for all the great time to be together 
with other labmates including Lara Reid, Jean Kwon, Ahmad Maarouf, Dr. Antony 
Thomas, Dr. Jia Hu, Dr. Doruk Yunus, Dr. Salman Sohrabi, Yuyuan Zhou, Shen Wang, 
and Meghdad Razizadeh: you guys are wonderful and thanks for all of the help. Outside of 
v 
 
the lab, firstly I would like to thank Dr. Nansen Lin, who inspired me to pursue a PhD 
degree abroad. And also thanks to Yongyang Huang, who performed a lot OCT scanning 
for my samples.  
Last but not least, I would like to delicate this dissertation to my family including my 
beloved wife, Qi (Angie) Meng, my cute son, Asa Shi, and beloved parents, Guangming 
Shi and Fengming Peng. Angie, it was you always supporting me when I confronted any 
obstacles and calmed down me when I obtained little success. And thanks to our recipe for 
keeping love fresh: To stay together is to stay together. Asa, it was your showing-up 
strengthened my sense of responsibility on family and career, and also it was you bringing 
so much happiness and fun to us. My parents, who always knew the strength of knowledge 
and provided endless support to help me pursue doctoral degree. As a single child, to be 
years of abroad from you was unfilial from my inside, but you not only never blamed me 
on this, but always gave me support when I needed. 
  
vi 
 
Contents 
List of Tables .................................................................................................................. ix 
List of Figures ................................................................................................................. x 
Abstract ........................................................................................................................... 1 
Chapter 1: Introduction ....................................................................................................... 4 
1.1 Background and Motivation ...................................................................................... 4 
1.2 Dissertation Layout ................................................................................................... 7 
Chapter 2: Magnetic particles assisted capture and release of rare circulating tumor cells 
using wavy-herringbone structured microfluidic devices ................................................... 9 
2.1 Introduction ............................................................................................................... 9 
2.2 Materials and Methods ............................................................................................ 11 
2.2.1 Materials ........................................................................................................... 11 
2.2.2 Microfluidic device design, fabrication and assembly ..................................... 12 
2.2.3 An alternative approach for wavy replicates fabrication .................................. 15 
2.2.4 Cell culture and harvest .................................................................................... 16 
2.2.5 Cell counting..................................................................................................... 17 
2.2.6 CTC capturing from whole blood ..................................................................... 17 
2.2.7 Cell regrowth after capturing ............................................................................ 18 
2.2.8 Clinical test ....................................................................................................... 18 
2.3 Results and discussion ............................................................................................. 19 
2.3.1 Magnetic particles distribution under different shear rates .............................. 19 
2.3.2 Effect of flow rate during cell suspension injection ......................................... 24 
2.3.3 Effect of Anti-EpCAM concentration .............................................................. 25 
2.3.4 Capture sparse CTC .......................................................................................... 26 
2.3.5 CTC capturing from whole blood using flow cytometer .................................. 27 
2.3.6 Regrowth of captured cells ............................................................................... 30 
2.3.7 Clinical test ....................................................................................................... 32 
2.4 Conclusions ............................................................................................................. 35 
Chapter 3: Isolation of white blood cells, circulating tumor cells, and circulating tumor 
cell clusters on the same microfluidic device by centrifugal force ................................... 36 
3.1 Introduction ............................................................................................................. 36 
vii 
 
3.2 Experimental ........................................................................................................... 40 
3.2.1 Spiral microchannel design .............................................................................. 40 
3.2.2 Fabrication ........................................................................................................ 41 
3.2.3 Flow experiments setup .................................................................................... 42 
3.2.4 Cell lines and man-made clusters ..................................................................... 43 
3.3 Results and Discussion ............................................................................................ 43 
3.3.1 Optimization of the spiral device ...................................................................... 43 
3.3.2 2-step method ................................................................................................... 51 
3.4 Conclusions ............................................................................................................. 54 
Chapter 4: Facile Tumor Spheroids Formation in Large Quantity with Controllable Size 
and High Uniformity ......................................................................................................... 56 
4.1 Introduction ............................................................................................................. 56 
4.2 Experimental ........................................................................................................... 60 
4.2.1 Materials and Cell Lines ................................................................................... 60 
4.2.2 MCTS Formation and Size Uniformization ..................................................... 60 
4.2.3 MCTS Characterization .................................................................................... 62 
4.2.4 Drug Test .......................................................................................................... 63 
4.3 Results and discussion ............................................................................................. 64 
4.3.1 Comparison between two types of typical 3D cell culture methods ................ 64 
4.3.2 Cellular Spheroids Formation Process using Dispase ...................................... 65 
4.3.3 Size Control ...................................................................................................... 70 
4.3.4 Cellular Spheroids Size Uniformization ........................................................... 71 
4.3.5 Toxicity of Dispase ........................................................................................... 75 
4.3.6 A few Characterizations of HCT116 Spheroids ............................................... 76 
4.3.7 Tumor Spheroids used in Drug Screening ........................................................ 80 
4.3.8 Other cell lines .................................................................................................. 83 
4.3.9 Advantages and improvements over existing methods, devices or materials .. 84 
4.4 Conclusions ............................................................................................................. 89 
Chapter 5: Bi-layer blood vessel mimicking microfluidic platform for tumor drug 
screening based on co-culturing 3D tumor spheroids and endothelial layers ................... 90 
5.1 Introduction ............................................................................................................. 90 
viii 
 
5.2.1 Materials ........................................................................................................... 93 
5.2.2 Drug .................................................................................................................. 95 
5.2.3 Design of microfluidic devices ......................................................................... 95 
5.2.4 Fabrication of the microfluidic devices ............................................................ 96 
5.2.5 Endothelial layer seeding (seed EC first) ......................................................... 97 
5.2.6 Tumor spheroid formation, harvest, filtering and seeding ............................... 97 
5.2.7 Drug Testing ..................................................................................................... 99 
5.2.8 Characterization ................................................................................................ 99 
5.3 Results and Discussion .......................................................................................... 103 
5.3.1 Dead and live staining .................................................................................... 103 
5.3.2 OCT scanning and volume information ......................................................... 104 
5.3.3 Co-culture of EC and HCT spheroids in the device ....................................... 106 
5.3.4 EC behavior in drugs ...................................................................................... 107 
5.3.5 Drug effect on HCT116 spheroids .................................................................. 109 
5.4 Conclusions ........................................................................................................... 112 
Chapter 6: Summary and Outlook .................................................................................. 114 
6.1 Wavy-HB structured microfluidic device for effective and selective capture and 
release of CTC ............................................................................................................. 115 
6.2 Spiral-channeled microfluidic device for CTC and CTCC isolation .................... 116 
6.3 Facile 3D tumor spheroid formation by dispase treatment and orbital-shaking ... 117 
6.4 Bi-layer blood vessel mimicking microfluidic platform for tumor drug screening
 ..................................................................................................................................... 119 
References ....................................................................................................................... 121 
Vita .................................................................................................................................. 134 
 
  
ix 
 
List of Tables 
Table 2.1 Identification of MM CTC, RCC CTC and WBC from patient samples. ........ 33 
Table 4.1 Advantages and disadvantages of our tumor spheroid formation method and 
other popular methods....................................................................................................... 87 
Table 4.2 Quantitative comparison between our method and other methods. The data of 
the three methods except Liquid Overlay were from [154]. ............................................. 88 
 
  
x 
 
List of Figures 
Figure 2.1 Cartoon illustration of the fabrication of the wavy-HB microfluidic devices. 
(A) (B) Sketch of the layout of the wavy-HB structures with the detailed parameters. (C) 
The shape of the apical channel. (D) Cross-section illustration of an assembled wavy-HB 
microfluidic device. (E) An assembled wavy-HB microfluidic device with food coloring 
green flow. (F) and (G) Typical microscope image of the wavy pattern and its 
profilometer result (the red dash line shows the direction of profilometric measurement). 
The blue and red arrows indicate the peak and trough of the wavy pattern, respectively. 
The lengths of two arrays mean 50 µm and 500 µm for vertical and horizontal directions, 
respectively in (G)............................................................................................................. 12 
Figure 2.2 Illustration of experimental steps of CTC capturing and release. .................. 14 
Figure 2.3 An alternative fabrication process of the wavy-HB master. PDMS groove 
patterns, which were used as templates, could be easily fabricated by soft lithography, 
and could be reused for more wavy pattern PDMS pieces fabrication. The introduction of 
strong vacuum removed most bubbles trapped between groove pattern and SU8 layer, 
thus ensured perfect groove replicates. Such wavy patterns were on glass slides, which 
were much cheaper than silicon wafers. ........................................................................... 16 
Figure 2.4 MPs distribution in wavy-HB pattern microfluidic devices at different MPs 
concentrations: (A-D) 0.239, 0.467, 0.893, and 1.64 mg/mL. The four images share the 
same scale bar in (D)......................................................................................................... 20 
Figure 2.5 (A) HCT116 tumor cells capture efficiency by wavy-HB pattern microfluidic 
devices based on different concentrations of MPs (n = 5). (B) is the capture efficiency 
comparison of wavy-HB pattern device, flat device, groove-HB pattern device and 
flipped wavy-HB pattern device with flat bottom (n = 5). One way ANOVA statistical 
analysis with Tukey equal variances assumed, along with tests of homogeneity of 
variance verified by Brown–Forsythe and Welch analyses, performed by OriginLab 8.5. 
Statistical significance indicated by * brackets in both plots at p < 0.05. Sample collection 
was carried out from 5 independent microfluidic devices (biological replicates). All 
statistical tests have been justified as appropriate. ............................................................ 21 
Figure 2.6 (A) typical microscope image of groove HB pattern, (B) MPs stabilized in 
groove HB pattern device and (C) MPs subjected to flow in groove HB pattern device. 22 
Figure 2.7 MPs (0.893 mg/mL) distribution after different flow rates of PBS flow. The 
flow rate used in (A-E) are the original, 0.5, 1, 2, 4 mL/h, respectively. (F) is the MPs 
found in the same trough after PBS flow. The flow volume of PBS is same for each flow 
rate, which means larger flow rate costs less time. The microscope images share the same 
scale bar in (A). ................................................................................................................. 23 
Figure 2.8 Effect of cell injection flow rate on capture efficiency (* means P < 0.05, 1-
way ANOVA and Tukey post-hoc test). ........................................................................... 25 
xi 
 
Figure 2.9 Effect of anti-EpCAM concentration on capture efficiency (* means P < 0.05, 
1-way ANOVA and Tukey post-hoc test). ....................................................................... 26 
Figure 2.10 Capture efficiency when dealing with low concentration of HCT116 cells. 
The lowest HCT116 cell concentration is 200/mL (50 µL suspension was flowed, 
resulting about 10 CTCs). With 1-way ANOVA and Tukey post-hoc test, no significant 
difference were found between different cell concentrations. .......................................... 27 
Figure 2.11 Capture efficiency from whole blood samples based on different tumor cell 
concentrations. (Black dots) Data obtained from flow cytometer, and (Blue dots) data 
obtained from manual counting. With 1-way ANOVA and Tukey post-hoc test, no 
significant difference were found between different cell concentrations. ........................ 29 
Figure 2.12 Flow cytometry results to show the selectivity of the CTC capture device. 
The events (red dots) showed the pre-stained tumor cells. Other events (black dots) that 
happened in the same range as the tumor cells outlined by red lines were counted, and 
these events were treated as impurities, which might include white blood cells, 
macrophages, and MPs clusters. The purity or selectivity was obtained by ..................... 30 
Figure 2.13 Re-culture of captured HCT116 cell sample. The sample had both captured 
HCT116 cells with MPs and individual MPs. (a)-(b) Cell re-culture on Day 1 and Day 4 
for Passage 0, respectively. (c)-(d) Cell re-culture for Passage1 and Passage 2, 
respectively. (e) Dead/Live staining images of captured HCT116 cells just after captured. 
Cells were linked because bare cell membrane attached to MPs on other cells during 
centrifuge. (f) Dead/Live staining images of captured HCT116 cells after 12 h incubation 
in petri dish. All the scale bars are 40 μm. And (a-d) share the same scale bar. As a 
collaborator of the project, Dr. Shunqiang Wang kindly provided figure (a-d), which were 
also shown in his dissertation. [26] ................................................................................... 32 
Figure 2.14 CTC enumeration results from tumor patient samples. (Upper) Quantitative 
results from 8 MM patient samples and 6 RCC patient samples. (Lower) Typical 
fluorescent images of CTCs and WBC from patient samples. ......................................... 34 
Figure 3.1 Illustration of Dean vortices in a curved rectangular channel. ....................... 39 
Figure 3.2 Illustration of the dimension of the 1.5 spiral channel. .................................. 41 
Figure 3.3 Standard soft lithography for fabrication of the spiral microfluidic device. .. 42 
Figure 3.4 Illustration of particle locations in 1.75 spiral channels at different flow rates. 
Red lines shown in the channel indicate particle locations. Since the particles were 
introduced from the sample inlets, they were present on the outer wall side of the spiral 
channels initially, however after running through the semi-circle channel (which gives the 
flow a very high De), they were transported to the inner wall side by Dean vortices. This 
indicated that the flow finished a half Dean cycle. The flow rate between 15 + 135 mL/h 
and 16 + 144 mL/h were also tested (C and D), which also showed that RBC exited from 
the inner outlet. ................................................................................................................. 45 
Figure 3.5 Particle location in the outlet area of 1.5 spiral channels at different flow rates. 
The numbers underneath each image indicate the two flow rates (mL/h) which were used 
xii 
 
in sample inlet and sheath inlet, respectively. At flow rates of 9 + 81 mL/h to 13 + 117 
mL/h, the majority of the particles exited from the larger outlet, which indicated that the 
flow finished one full Dean cycle. The three spiral channel figures show the typical 
particle locations in the channel at different flow rates. ................................................... 46 
Figure 3.6 Fluorescent images of cells exiting from the two outlets of the 1.5 spiral 
channels at different flow rates after being initially well mixed. WBCs were pre-stained 
with Calcein AM and HCT116 single cells and clusters were pre-stained by CellTracker 
Red. ................................................................................................................................... 48 
Figure 3.7 Quantitative estimation of relative cell counts from the two outlets of the 1.5 
spiral channels at different flow rates. .............................................................................. 49 
Figure 3.8 Illustration of motion trail for CTCC (green line), CTC (blue line) and WBC 
(yellow line) in the spiral channels at lower and higher flow rates. For better 
visualization, straight channels were used. ....................................................................... 51 
Figure 3.9 Illustration of the 2-step method for WBC, CTC and CTCC isolation using the 
spiral channels. .................................................................................................................. 52 
Figure 3.10 Typical fluorescence images of the cells collected from both outlets. The left 
two images were cells collected in step 1 experiments; the right two images show the 
cells collected in step 2. Except for the small outlet in step 1, all other three samples were 
concentrated and put into a well of 96 well plate to show better visual results because the 
cells were highly concentrated. All four of the images share the scale bar in left upper. 52 
Figure 3.11 Quantitative results of the 2-step flow experiment performed on a 5 mL 
sample loaded with 10 CTCC, 100 CTC, and 1,000,000 WBC. The WBC from small 
outlet in left figure was more than 100,000, which was much more than other values in 
the figure, so it is not accurately shown in the figure. (* means P < 0.05, 1-way ANOVA 
and Tukey post-hoc test). .................................................................................................. 54 
Figure 4.1 Illustration (A) and the sample photos (B and C) of the autoclavable Sieves 
for Spheroid Size Uniformization. (D) Typical microscope image of a 149 µm stainless 
steel mesh, showing square holes with 149 µm side length. Spheroids that are filtered 
through this type of square mesh could be slightly larger than the mesh size, because they 
are soft and can squeeze to pass through the mesh. .......................................................... 62 
Figure 4.2 Comparison of HCT116 cells on 2D petri dish culturing (A), 3D spheroids 
culturing in ultralow attachment well plate (B), and 3D spheroids culturing in Matrigel 
(C). The three different cell culturing methods show a remarkable difference in cell 
behavior and cell morphology. ......................................................................................... 65 
Figure 4.3 Cartoon illustration of cellular spheroids formation. Single cells are seeded 
onto petri dishes (A), and after a few days of growth, cell sheets would form (B). Cell 
sheets can be detached off petri dishes by dispase and the sheets can be maintained (C). 
Shaking the cell sheets in dispase-doped media would let their edges folding (D) and 
eventually the cell sheets would become spheroids (E). ................................................... 66 
xiii 
 
Figure 4.4 Contrast microscope images of HCT116 tumor spheroids formation process. 
(A) HCT116 cell sheet (Sheet growth = 10 days) on petri dish and (B-E) cell sheet was 
detached by dispase and kept orbital-shaking at 30 rpm with dispase doped medium (1/6) 
for different time. All scale bars are 200 µm. ................................................................... 66 
Figure 4.5 Secondary flow induced Spheroid collection at the center of the petri dish 
under orbital shaking......................................................................................................... 67 
Figure 4.6 A few control experiments for tumor spheroids formation. (A) Controlled by 
using dispase-free media when shaking, the image was taken at shaking day 1; (B) 
Controlled by stopping shaking for 24h at day 7; and (C) Controlled by using large cell 
sheet (Sheet growth = 15 days), the image was taken at shaking day 5. All scale bars are 
200 µm. ............................................................................................................................. 69 
Figure 4.7 Size control of HCT116 tumor spheroids. (A) Size comparison of spheroids 
from cell sheets cultured on petri dishes for different time (6 days to 13 days). Spheroid 
size was recorded on different shaking days (black, red, green and blue dots are recorded 
on shaking day 3, 5, 7, and 9, respectively). (B) Size comparison of spheroids from cell 
sheets that were from different initial cell seeding density. Spheroid size was recorded for 
12 days. Each data were obtained from at least 7 tumor spheroids. ................................. 71 
Figure 4.8 HCT116 tumor spheroids size uniformization. (A) A typical image showing 
the widely size-distributed tumor spheroids, taken at shaking day 7 (detached at sheet-
growth day 9). (B-G) Tumor spheroids from the same batch as (A) filtered by different 
sieves. (H-N) Tumor spheroids size distribution before and after filtration, vertically 
corresponding to (A-G). The numbers such as 149-177 in (I) mean such spheroids are 
filtered by using sieves with such size (µm) holes. Each spheroids count were counted 
and calculated from 10-30 images taken at certain size distribution. All scale bars are 200 
µm. .................................................................................................................................... 73 
Figure 4.9 HCT116 spheroids from 120-144 μm sieves. (upper) Low magnification 
image of highly packed spheroids, and (lower) 96 randomly picked spheroids transferred 
to 96 well-plate. Scale bar in the middle = 200 µm. ......................................................... 74 
Figure 4.10 Dead/Live staining fluorescence images for two typical HCT116 spheroids 
shaken with (A) and without (B) dispase. The size change of the two comparable 
spheroids was also recorded for 10 days, and the results are shown in (C), indicating that 
there was negligible difference between with and without dispase treatment. APH 
experiments (see next part) were also performed to prove the argument, and results are 
shown in (D). Only a single size of spheroid was studied (around 400 µm), and at least 12 
spheroids were used for each point in (D). (E) Dot plot results show that the cell to cell 
junction protein E-cadherin was not affected by continued dispase treatment. Scale bars = 
200 µm. ............................................................................................................................. 76 
Figure 4.11 Fluorescence microscope images of a typical small (A) and large (B) 
HCT116 spheroids with Dead/Live staining. Scale bars = 200 m.................................. 77 
xiv 
 
Figure 4.12 Histology of HCT116 tumor spheroids. (A) A relatively smaller spheroid 
with about 250 μm diameter, and (B) a relatively larger spheroid with about 520 μm 
diameter............................................................................................................................. 78 
Figure 4.13 Two-dimensional (2D) phase contrast microscopic image of a large tumor 
spheroid with a measured diameter of 1205 µm. B. 2D cross-sectional image of the tumor 
spheroid obtained by optical coherence tomography (OCT). OCT is able to detect back-
scattered light within the tumor spheroid from depths close to 1 mm below the top 
surface of the spheroid. C. 2D top view image of the tumor spheroid by OCT. D. 3D 
rendering of the tumor spheroid by OCT to characterize the overall shape and size of the 
tumor spheroid. E. 2D bright field image of a small tumor spheroid with a measured 
diameter of 558 µm. F. 2D cross-sectional image of the small tumor spheroid by OCT. G. 
2D top view image of the small tumor spheroid by OCT. H. 3D rendering of the small 
tumor spheroid by OCT. With this culture method, tumor spheroids can retain a spherical 
shape for a long time with their diameters growing over 1 mm. ...................................... 79 
Figure 4.14 The relationship between live cell number of single cell suspension in a well 
of 96 well-plate and its absorbance at 405 nm on a well-plate reader (A), and the 
relationship between live cell number of spheroids with different sizes and live cell 
numbers (B). Both showed a linear relationship. (B) was plotted with about 130 spheroids 
with size ranging from 300 µm to 1200 µm. .................................................................... 80 
Figure 4.15 Spheroid integrity after treatment with Paclitaxel and Doxorubicin. 
Representative phase contrast images of the original spheroids (A), controlled spheroids 
after 72 h non-drug treatment (B), spheroids with 10 nM (C) and 500 nM (D) Paclitaxel 
for 72 h, and spheroids with 10 nM (E) and 500 nM (F) Doxorubicin for 72 h. Similar 
size spheroids (diameter ~500 µm) were treated with different concentrations of 
Paclitaxel and Doxorubicin for 72 h, and (A) shows a typical controlled spheroid, while 
(B) shows a spheroid that was treated by 300 nM Paclitaxel for 72 h. All scale bars are 
200 µm. ............................................................................................................................. 82 
Figure 4.16 The drug effect on HCT116 tumor spheroids by APH assay. Drug effects of 
Paclitaxel (A) and Doxorubicin (B) in spheroids cultures, with comparison to monolayer 
cell cultures. Dose-response curves were plotted exponentially. ..................................... 83 
Figure 4.17 3D rendered OCT images of spheroids after drug treatment for 72 h: (A) 
Control, (B) Paclitaxel (500 nM), and (C) Doxorubicin (500 nM). The initial size of 
spheroids was about 250 µm. ............................................................................................ 83 
Figure 4.18 Other cell lines can also form high quality and high uniformity robust 
spheroids by using this method. (A) Typical microscope image of HeLa tumor spheroids 
shaken for 14 days from cell sheet culturing for 7 days; (B) Typical microscope image of 
A431 tumor spheroids shaken for 4 days from cell sheet culturing for 7 days; and (C) 
Typical microscope image of U87 MG tumor spheroids shaken for 9 days from cell sheet 
culturing for 9 days. Scale bars = 200 µm. ....................................................................... 84 
xv 
 
Figure 5.1 Diagram of microfluidic devices using PDMS molds with basal and apical 
channels. The basal channel is the straight channel on the bottom layer of the device, 
where cells like human colon cancer cells (HCT116) can be grown. The next layer is the 
semi-permeable membrane and the top layer is the apical channel, which is the Z-shaped 
channel. Media is added to the apical channel and nutrients go through the membrane to 
the cells in the basal channel. Waste can be transported back through the membrane to the 
apical channel and removed from the apical channel outlet. ............................................ 94 
Figure 5.2 Longitudinal cross-section diagram of the bi-layer blood vessel mimicking 
microfluidic device. .......................................................................................................... 98 
Figure 5.3 Diagram of how to use FIJI to enumerate cells in highly packed condition. 
(A)(B), transfer color images to 16-bit gray-scale images. (B)(C), tune threshold to 
remove most of out-of-focus cells and keep most of the in-focus cells. (C)(D), run 
Watershed in FIJI to distinguish the highly packed cells. Run Analyze Particles function 
to count the cells in image D........................................................................................... 101 
Figure 5.4 Confocal and bright field images of a HCT116 spheroids in the bi-layer 
device. (A) Calcein AM stained, (B) PI stained, (C) stack of (A) and (B), and (D) bright 
field image. ..................................................................................................................... 103 
Figure 5.5 OCT scanning images of HCT116 spheroids in the device. (A) Cross-section 
of a HCT116 spheroid perpendicular to the channels, (B) cross-section of the spheroid 
parallel to the membrane, and (C) a 3D rendered OCT image of the spheroid. (A) and (B) 
share the same scale bar in (B). ...................................................................................... 105 
Figure 5.6 Co-culture of EC and HCT spheroids in the device. This is a fluorescence 
image in which both cell types were stained by CellTracker Green. The image was taken 
from the apical side of the device. .................................................................................. 106 
Figure 5.7 Confluent EC in the device subjected to a 3-day treatment of different 
concentrations of Paclitaxel. (I) Relative viability of EC after 3-days of exposure to 
different concentrations of Paclitaxel treatment. ............................................................ 107 
Figure 5.8 Confocal images of HCT116 spheroids subjected to 3-day 100 nM Pac 
treatment at different conditions. All the images were split to green and red channels to 
more vividly show the live and dead cells. ..................................................................... 109 
Figure 5.9 The volume change of HCT116 spheroids in EC loaded channels monitored 
by OCT subjected to different concentrations of Paclitaxel for up to 72 h. (* means P < 
0.05, 1-way ANOVA and Tukey post-hoc test). ............................................................ 111 
Figure 5.10 The relative viability of HCT116 cells in EC loaded channels subjected to 
different concentrations of Paclitaxel for 72 h in well plates (A), in EC free channels (B), 
and in EC loaded channels (C). All the three figures share the same legend in the middle. 
(* means P < 0.05, 1-way ANOVA and Tukey post-hoc test). ...................................... 112 
Figure 6.1 Illustration of how to realize size filtering automation. ................................ 119 
  
1 
 
Abstract 
Circulating tumor cells (CTC) play a significant role in the process of tumors becoming 
life-threatening. The appearance of CTC in the circulatory system of cancer patients is 
deemed the start of metastasis. Obtaining CTC from blood is critical for many biomedical 
applications, such as using CTC for DNA sequencing to reveal the gene difference between 
CTC and tumor cells at the original site, creating in vitro tumor models based on CTC, and 
developing new and effective therapeutic schemes, etc. Based on this, the focus of the 
dissertation is mainly on CTC research. In brief, the dissertation demonstrates several 
techniques on how to isolate CTC from patient blood samples, how to use CTC in the 
formation of 3D tumor models, and how to use these 3D tumor models for highly 
efficient anti-tumor drug screening.  
First, a wavy-herringbone (wavy-HB) structured microfluidic device is developed to 
effectively and selectively capture and release CTC by using immunoaffinity and magnetic 
force. The device is designed to create passive turbulence and increase the possibility of 
tumor cells colliding onto the device wall. Under an external magnetic field, magnetic 
particles (MPs) coated with anti-EpCAM against tumor cell surface protein (EpCAM) are 
immobilized over the wavy-HB surface to capture tumor cells. After removing the 
magnetic field, the captured cells with surplus MPs are released from the device and 
collected, thus cells can be re-cultured for further analysis. Under optimized conditions, 
the capture efficiency of tumor cells can be as high as 92%±2.8%. Capture experiments are 
also performed on whole blood samples and the capture efficiency is in the high range of 
81%-95%, based on different tumor cell concentrations.  
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Next, to isolate CTC clusters (CTCC), which have been shown to have higher invasiveness 
than CTC, a spiral channeled microfluidic device is introduced. Utilizing the centrifugal 
force created within the spiral channels, the device can isolate three types of cells, i.e. white 
blood cell (WBC), CTC, and CTCC. Due to the size difference among these cells, when 
introduced into the microfluidic device, the centrifugal forces they experience are different, 
which enables them to exit from different outlets of the device. At lower flow rates, WBC 
can first be isolated, while CTC and CTCC are isolated at higher flow rates. This device is 
able to isolate rare CTC and CTCC from massive WBC.  As such, the device coupled with 
the proposed method can potentially be used for isolation of CTC and CTCC from patient 
blood samples. 
To use the CTC and CTCC obtained from the first two techniques, a facile method for the 
generation of tumor spheroids in large quantities with controllable size and high uniformity 
is presented. HCT116 cells are used as the model cell line. Individual tumor cells are 
sparsely seeded onto petri-dishes. After a few days of growth, separated cellular islets are 
formed and then detached by dispase while maintaining their sheet shape. These detached 
cell sheets are transferred to dispase-doped media and maintained under orbital shaking 
conditions. Assisted by the shear flow generated as a result of the shaking and inhibition 
of cell-to-extracellular matrix junctions by dispase, the cell sheets curl up and eventually 
tumor spheroids are formed. The average size of the spheroids can be controlled by tuning 
the cell sheet culturing period and spheroid shaking period. The uniformity can be 
controlled by a set of sieves which were custom-made using stainless steel meshes. Since 
this method is based on simple petri-dish cell culturing and shaking, it is rather facile for 
forming tumor spheroids with no theoretical quantity limit. This method has been used to 
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form HeLa, A431 and U87 MG tumor spheroids and application of the formed tumor 
spheroids in drug screening is also demonstrated. The viability, 3D structure, and necrosis 
of the spheroids are characterized. 
Finally, to more closely mimic the microenvironment of in vivo tumors, a bi-layer 
microfluidic device is presented to facilitate anti-tumor drug screening. The bi-layer 
microfluidic device consists of two PDMS pieces with channels which are separated by a 
semi-permeable membrane to allow water, oxygen and nutrition supply while preventing 
cell migration. The channels on the two PDMS pieces overlapping each other over a long 
distance to ensure a larger exchange area to mimic the blood vessel-tumor model. High 
concentrations of EC are first seeded onto the membrane through the apical channel, and 
after a two-day culture to ensure a confluent EC monolayer forms, tumor spheroid laden 
Matrigel is seeded into the basal channel. After the Matrigel is cured, the device is ready 
for drug testing. Confocal and ImageJ are used to assess the efficacy of different 
concentrations of drugs and combination of drug therapies. Optical coherence tomography 
is employed to determine the tumor shrinkage after drug treatment. 
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Chapter 1:  Introduction 
1.1 Background and Motivation 
According to the American Cancer Associates study, cancer is one of the leading causes of 
death  in  both  developed  and  developing  countries [1]. The number of cancer deaths in 
2012 worldwide was 8.2 million, and 14.1 million new cancer cases were diagnosed in 
2012 worldwide [2]. What is more, these numbers continue to grow with 21.7 million new 
cancer cases expected to be diagnosed in 2030, 13 million cancer deaths are predicted in 
the same year [1]. Because of the high appearance rate and high death rate, governments 
and companies have devoted a lot of money and time into research of cancers [3], [4]. 
There are two main research directions: early prevention of cancer and the effective 
treatment of existing cancer, both of which have acquired great success. The principle of 
early cancer prevention is the early diagnosis of tumors, because it means higher survival 
rate [5]–[8], while the principle of effective treatment of existing cancer is developing and 
utilizing effective drugs or therapies that only harm to tumor cells [9]–[11]. 
To diagnose a cancer, the traditional method is tissue biopsy [12], [13], which is the study 
of the tissue or cell sample extracted from patients. Biopsies require an invasive removal 
of tissue in the region of interest, which creates a lot of pain and discomfort for patients 
[12], [14]. As a result, a new method called non-invasive liquid biopsy which studies 
biomarkers from patient blood sample is attracting more attention [15], [16]. Biomarkers 
in patient blood samples have been vastly studied in non-invasive liquid biopsies, including 
antibodies, enzymes, proteins, DNA, RNA and circulating tumor cells (CTCs) [17], [18]. 
Among these biomarkers, CTCs behave as a highly effective indicator for cancer status 
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[17], [18]. Clinical studies have been pursued to support the view that detection of CTCs 
can be achieved several years before the traditional diagnosis, thus providing high chances  
for patients to survive before severe cancer growth occurs [19], [20]. What is more, the 
population of CTCs also provides prognostic information, which has been approved by 
FDA and demonstrated to predict overall survival rate in different types of tumor patients 
[5], [7], [8], [21]. Although CTCs can offer plenty of valuable information, CTCs in blood 
are rare, which increases the difficulty of isolating them, and this encourages a lot of 
researchers to develop a variety of methods [22]–[25]. Remarkably, because of the 
dramatic population difference of rare CTCs and other cells (a few billions), CTC isolation 
faces two technical challenges: (1) How to obtain high CTC isolation efficiency, meaning 
the ability to acquire as many CTCs as possible in a certain amount of blood; (2) How to 
obtain high CTC isolation selectivity, meaning the ability to acquire as many pure CTCs 
as possible with little of the other blood cells. The first challenge requires a solution for the 
accuracy problem, while the second one targets the post-process of CTCs, such as regrowth, 
tumor models and DNA sequencing. A series of research reported relatively high capture 
efficiency (over 80%) with high levels of selectivity for CTCs from blood, but few of them 
focused on isolation and acquisition of CTCs. Our group also reported a method using 
wavy-herringbone patterned microfluidic devices to achieve high capture efficiency [26], 
but the CTCs were immobilized in the devices, so the method only provided enumeration 
information with none of the CTCs being used for post-analyses.  
To treat a cancer, three main clinical techniques are normally used: excision [27], 
chemotherapy [28] and radiotherapy [29]. Excision is rather effective on cancers at early 
stages, with no metastasis, which is defined as the transfer of cancer cells from the primary 
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tumor to other sites of the body [30]. Once metastasis occurs within a patient, excision is 
not sufficient to remove all of the invasive tumor cells, and chemotherapy and radiotherapy 
are required. Between these two therapies, chemotherapy is more widely used because of 
the large variety of drugs developed and the insightful knowledge of molecular cell biology 
[28], [29], [31]–[33]. To develop an effective tumor drug, there is a process called tumor 
drug screening, which basically picks one or a few effective drugs from many candidates. 
Traditional tumor drug screenings utilize 2D cell monolayers, which are not a practical 
recreation of tumors in vivo, and thus lead to longer times and higher costs required for 
animal and clinical trials [34]–[36]. 3D in vitro tumor models have also been widely studied 
for tumor drug screening [35], [36], however due to the limitation of 3D tumor formation 
methods, 3D tumor models used in tumor drug screening face two main technical 
challenges: (1) How to facilely and effectively form 3D in vitro tumor models in large 
quantity with controllable size and high uniformity, and (2) How to achieve a close 
mimicking of tumors and their in vivo microenvironment. The first challenge aims at 
producing easily accessible 3D in vitro tumor models for anti-tumor drug screening, in 
order to not only enhance the drug screening efficiency but also decrease the cost of 
developing new drugs. The second challenge further provides tools or platforms for anti-
tumor drug screening, which further enhances the efficiency and decrease costs. 
To overcome these challenges, microfluidics were involved and have made great progress. 
Microfluidic devices, which just emerged in recent decades, have been well-studied and 
applied in a lot of different areas, such as chemical, electrical, biomedical and 
environmental engineering [37]–[42]. By using microfluidics, the device miniaturization 
results in low waste, low cost, high efficiency and controllable flow rate and concentration 
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gradient [39], [42], which are economically and effectively beneficial to both CTC capture 
[43] and anti-tumor drug screening [43]. Three out of four Chapters in this dissertation 
utilize microfluidics. 
1.2 Dissertation Layout 
Herein, the dissertation layout is organized as below. First two types of CTC and CTC 
cluster isolation methods are introduced, and the emphasis is made on how to enhance the 
isolation efficiency and selectivity. To find applications of these isolated CTC, a novel 
method that can use tumor cell lines or isolated CTC to form tumor spheroids is then 
introduced. Last, a bi-layer microfluidic platform mimicking the blood vessel to tumor 
microenvironment is designed for tumor drug screening using the formed tumor spheroids. 
In detail, the layout is as follows.  
Chapter 1 briefly describes the background and main challenges faced in CTC capturing 
and tumor drug screening areas, and the detailed introduction and motivation will be 
demonstrated in each of the following chapters.  
Chapter 2 presents a CTC isolation platform that can be used for effective and selective 
capture and release of CTCs by using wavy-herringbone structured microfluidic devices 
and magnetic particles, and the results when applied on real samples. 
Chapter 3 introduces a spiral microfluidic device that can be used for isolation of white 
blood cells (WBC), single CTCs and CTC clusters by centrifugal force created by curved 
micro-channels, showing rather high isolation performance. 
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Chapter 4 describes a novel and facile method that can be used for the generation of tumor 
spheroids in large quantity with controllable size and high uniformity by using dispase and 
a set of custom-made sieves, which shows great advantages on yield and performance over 
current popular tumor spheroid formation methods.  
Chapter 5 presents a double-layered microfluidic platform, which mimics blood vessels for 
the application of tumor drug screening based on co-culturing 3D tumor spheroids and 
endothelial layers, as well as well-defined drug tests on the platform. 
Chapter 6 summarizes the dissertation and presents indications for future work. 
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Chapter 2:  Magnetic particles assisted 
capture and release of rare circulating 
tumor cells using wavy-herringbone 
structured microfluidic devices 
2.1 Introduction 
Circulating tumor cells (CTCs) are originated from the primary tumor site and circulate 
over the course of metastasis. CTCs were among the several general cancer biomarkers 
which could be used for cancer detections [21] and cancer prognostics [44], [45]. Various 
techniques were thus developed to isolate CTCs in recent decades, which were categorized 
into either positive CTC isolation [46]–[48] or negative leukocytes depletion [49], [50].  In 
other words, these techniques were either based on physical property differences or 
immunoaffinity differences between CTCs and normal blood cells including both red blood 
cells (RBCs) and white blood cells (WBCs). Among such techniques, microfluidic systems 
show outstanding advantages on CTC differentiation, because they enable generic and 
consistent miniaturization, integration, automation and parallelization of (bio-)chemical 
processes [51]–[55]. There are plenty of microfluidic assisted CTC differentiation 
researches by using different properties of CTCs from other healthy cells, such as the size 
difference [56], [57], cell surface marker difference [52], [58], and electrical property 
difference [58]. However, techniques using CTC surface marker difference show a higher 
selectivity and higher capture efficiency due to the uniqueness of surface markers on 
certain CTCs. For example, based on the fact that most CTCs uniquely express epithelial 
cell adhesion molecules (EpCAM), Toner's group developed a few microfluidic chips 
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coated with the corresponding antibody, i.e. anti-EpCAM, to capture CTCs [46], [52]. The 
device performance was examined on various cancer types and demonstrated with a high 
capture efficiency of ~85%, which was essential for further clinical utility [59], [60]. In 
these approaches, CTCs captured in the microfluidic chip were subjected to fluorescent 
staining and then imaged/counted through microscopic analysis. Besides the in-situ CTC 
analysis, there was a need for isolated CTCs to be collected and re-cultured which allows 
for further applications, such as drug screening and treatment guidance [61], [62]. This, in 
turn, required isolated CTCs to be released from the capture bed. A few attempts were 
made by implementing stimulated subjects such as aptamers [63], [64] and thermo/PH-
responsive materials [65], [66]. An alternative which was currently widely studied was to 
use magnetophoresis to isolate either CTCs or WBCs labeled with corresponding 
immunomagnetic particles [67]–[70].  
Toner's group developed a CTC-iChip which first depleted RBCs based on deterministic 
lateral displacement and then negatively extracted all WBCs labeled with immunomagnetic 
particles by applying a magnetic field [70]. Similarly, Liu et al. [71] developed a 
microfluidic chip embedded with Nickel micropillars, which positively isolated CTCs 
labeled with anti-EpCAM coated magnetic particles (MPs) under a magnetic field. 
Although these techniques advanced CTC post-analysis, further improvements mainly lie 
in a development of a platform with high capture efficiency, high release efficiency, and 
easy fabrication/operation modality. Liu group previously developed a microfluidic chip 
with hierarchical micro/nanostructures for CTC capture with high capture efficiency and 
high purity [72]–[75]: high capture efficiency was mainly attributed from the Herringbone 
(HB) structures induced vortex effect and further enhanced by the micro- and 
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nanostructures. High purity was achieved by smoothing the sharp grooved patterns into 
wavy patterns, thus eliminating the low-shear regions where WBCs were subjected to non-
specific capture. In this work, by extending such platform, instead of permanently 
depositing particles through immunoaffinity, anti-EpCAM coated MPs were trapped over 
the untreated PDMS surface by external magnetic field and were then released by readily 
removing the magnet for CTC collection. To obtain an optimal experimental condition, 
different experiment parameters are used and discussed. As a proof-of-concept, flow 
cytometer analysis was used in this work to evaluate the device performance in real blood 
samples. Finally, captured cancer cells labeled with MPs were collected and re-cultured in 
regular tissue culture petri dishes to demonstrate the capability for further applications such 
as tumor drug screening. 
2.2 Materials and Methods 
2.2.1 Materials 
The media used for HCT116 cells is Dulbecco’s Modified Eagle’s Medium (DMEM, Life 
Technology), with 10% fetal bovine serum (FBS, Invitrogen) and 1% Antibiotic & 
Antimycotic (ThermoFisher). Fluorescence dyes (Calcein AM, Ethidium Homodimer, 
Propidium Iodide (PI) and CellTracker Green) are purchased from ThermoFisher. SU8-
2050 is a product of MicroChem. PDMS is Sylgard 184 from Dow Corning. MPs coated 
with streptavidin (diameter 1 µm, Dynabeads MyOne Streptavidin T1, Invitrogen), 
biotinylated Anti-EpCAM (Life Technology) and Bovine serum albumin (BSA, Sigma-
Aldrich) are used without purifying. Whole blood samples are from Innovative Research. 
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RBC lysing buffer is purchased from Sigma-Aldrich. Other chemicals that are not 
mentioned are used directly without purifying. 
 
Figure 2.1 Cartoon illustration of the fabrication of the wavy-HB microfluidic devices. (A) 
(B) Sketch of the layout of the wavy-HB structures with the detailed parameters. (C) The 
shape of the apical channel. (D) Cross-section illustration of an assembled wavy-HB 
microfluidic device. (E) An assembled wavy-HB microfluidic device with food coloring 
green flow. (F) and (G) Typical microscope image of the wavy pattern and its profilometer 
result (the red dash line shows the direction of profilometric measurement). The blue and 
red arrows indicate the peak and trough of the wavy pattern, respectively. The lengths of 
two arrays mean 50 µm and 500 µm for vertical and horizontal directions, respectively in 
(G). 
2.2.2 Microfluidic device design, fabrication and assembly 
The structure of the wavy HB is well designed in our previous studies [76], as shown in 
Fig. 2.1(B). The fabrication of the microfluidic device can be readily understood from Fig. 
2.1(A). Briefly, groove HB pattern on a silicon wafer was obtained by photolithography 
with SU8-2050, and PDMS replicate was generated by the groove HB pattern. Another 
wafer was spun with SU8-2050 and after 95°C soft baking, and the obtained PDMS groove 
HB pattern was placed on top of the SU8 at 95°C baking. After cooling down, the PDMS 
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piece was removed and the resulted SU-8 groove pattern was heated at 55°C for about 10 
min, and the shape SU-8 groove pattern would become a wave-like pattern, as shown in 
the small figure in Fig. 2.1(A). The fabrication was finalized by UV exposure (365 nm with 
an intensity of 4.6 mW cm−2) on the whole silicon wafer to cure SU-8 and stabilize wavy 
pattern, a silicone-fluoro reagent (Perfluorodecyltrichlorosilane) coating was used for 
reducing the adhesion between SU-8 and PDMS. To form a chamber, another mode with 
the pattern of Fig. 2.1(C) was also made by photolithography and the height was 50 µm. 
PDMS pieces were replicated from both the wavy HB mode and the channel mode. Punch 
holes on the channel PDMS piece at the circles and bind them together with an oxygen 
plasma treatment. After assembly, the device had a cross-section which was illustrated in 
Fig. 2.1(D), and the formed chamber was called wavy chamber. When using, the wavy HB 
piece was always at the bottom, so it was named as the basal piece, while the channel piece 
was the apical piece. 
The device was autoclaved before use. MPs coated with streptavidin, Anti-EpCAM and 
PBS were mixed and incubated for 1 h. During the incubation, remix them every 20 min 
by tapping several times on a vortex to ensure a strong bonding between MPs and Anti-
EpCAM. Meanwhile, the device, any tubes that would contact cells, and syringes were 
incubated with 3% BSA in PBS for 1 h to minimize non-specific bonding. After incubation, 
MPs mixture was remixed and injected into the device. The distribution was normally not 
fully even, so the wavy chamber was slightly tapped and then the device was rapidly placed 
on a flat Neodymium magnet. The device was kept on the magnet until cell capture 
experiment finishing. PBS at 2 mL/h was flowed through the chamber to remove any free 
anti-EpCAM. Then 20 µL cell suspension was injected at different flow rates and another 
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PBS flow at 2 mL/h was used to remove non-binding cells. Liquid from the outlet was 
collected during cell suspension injection and PBS washing. After 200 µL PBS washing at 
2 mL/h, to release the captured cells, the magnet was removed, and another container was 
used to collect the liquid from the outlet by PBS washing for 200 µL. Additional 1 mL PBS 
was flowed into the channel at 10 mL/h to ensure no cells were left in the system (tubes 
and chamber). Fig. 2.2 shows the experimental steps of CTC capturing and release. 
 
Figure 2.2 Illustration of experimental steps of CTC capturing and release. 
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2.2.3 An alternative approach for wavy replicates fabrication 
As Fig. 2.3 shown, a droplet (1-2 mL) of SU8 was put on a glass slide, and a spatula was 
used to paint the SU8 to form a rectangular shape which was larger than the PDMS groove 
template. The template was placed on the SU8 coated area, and it was tapped slightly to 
ensure a good contact. Then the slide was placed on 95°C hot plate for 1 min, and it was 
put onto a stack of glass slides which were preheated to about 100°C in an oven. The whole 
piece of glass slides and the template were vacuumed to remove the bubbles trapped in the 
groove pattern. The vacuum should be close to or stronger than -29 inchHg and it was kept 
for 1 min. Then the slide with the template was put in a 95°C oven for 30 min to remove 
most of the solvents and possible bubbles. After it cooled down, the template was peeled, 
and the slide was placed on a 55°C hot plate for 3-10 min. The reflow time was determined 
by the amount of residual solvents in SU8, so checkup every 10 s was needed to ensure 
there was no over-flow to destroy the wavy pattern. Finally, the wavy-HB SU-8 pattern 
was UV cured at 365 nm with an intensity of 4.6 mW/cm2 for 100-200 s. The micropattern 
topography and morphology was examined by a profilometer and an optical microscope. 
Due to thermal reflow, the final pattern depth decreased from 63 μm (grooved-HB) to 45 
μm (wavy-HB). To ensure the wavy-HB chip has a similar depth of the grooved-HB chip 
for later cell capture comparison, we used the grooved-HB chip with a groove depth of 45 
μm. 
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Figure 2.3 An alternative fabrication process of the wavy-HB master. PDMS groove 
patterns, which were used as templates, could be easily fabricated by soft lithography, and 
could be reused for more wavy pattern PDMS pieces fabrication. The introduction of strong 
vacuum removed most bubbles trapped between groove pattern and SU8 layer, thus 
ensured perfect groove replicates. Such wavy patterns were on glass slides, which were 
much cheaper than silicon wafers. 
2.2.4 Cell culture and harvest 
The human colorectal cancer cell line, HCT116, was used as a model CTC in this work. 
Cultured in 5% CO2 and at 37 °C, HCT116 cells were incubated with DMEM 
supplemented with 10% FBS and 1% Antibiotic & Antimycotic. The medium was changed 
every 2 days. When the cells reached 80-90% confluency, they were subcultured and 0.05% 
Trypsin - 0.53 mM EDTA was used for cell detachment. Since individual cells were needed 
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in this study, cells were obtained from about 10% confluency to prevent cell clusters 
forming. To reduce the cell sedimentation in the tube during the flow test, cells used in 
non-blood tests were in 4 mg mL−1 alginated. 
2.2.5 Cell counting 
After at least 4 h of incubation of the captured cells, 3.7%v. formalin PBS solution was 
used to fix them for 5-10 min, followed by incubating in 0.1% Triton x-100 for 10 min at 
room temperature to permeabilize the cell membrane. PI (1 µg/mL) was used to stain the 
cells and the incubation time was 15 min. The number of captured cells was calculated by 
counting the fluorescent cells under a fluorescence microscope, and the number of 
uncaptured cells calculated by counting the cells from the second PBS washing based on 
the same staining protocol. The capture efficiency is defined as 
𝐶𝑎𝑝𝑡𝑢𝑟𝑒 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
# 𝑜𝑓 𝐶𝑎𝑝𝑡𝑢𝑟𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
# 𝑜𝑓 𝐶𝑎𝑝𝑡𝑢𝑟𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 + # 𝑜𝑓 𝑈𝑛𝑐𝑎𝑝𝑡𝑢𝑟𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
When calculating CTC capture efficiency determination in real blood samples, it is 
impossible to count CTCs embedded in extremely massive blood cells, so additional steps 
were needed. 
2.2.6 CTC capturing from whole blood 
For blood tests, HCT116 cells need to be pre-labeled because of the massive cell quantities. 
The counting method mentioned above does not work in this case. The fluorescent dye, 
CellTracker Green, which has low cytotoxicity, is a good choice for this purpose. HCT116 
cells were harvested by centrifugation and the supernatant was aspirated, followed by 
resuspended in 5 µM CellTracker Green (Life Technology). The mixture was incubated 30 
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min in an incubator and the cells were collected by centrifugation and aspiration. The cells 
were resuspended in PBS for a high concentration (~106/mL), and a certain volume of the 
suspension was added into whole blood to form a series of tumor cell concentrations of 
samples (100, 200, 500, 1000, 2000, 5000, 10000/mL). 50-500 µL tumor cell spiked blood 
samples were used for capturing experiments, following the same protocol mentioned 
above. Since only tumor cells were stained and only tumor cells could be captured, 
captured tumor cells can be counted under a fluorescence microscope, or by using ImageJ, 
but the uncaptured tumor cells was hard to identify because they were buried in massive 
blood cells. Therefore, red blood cells (RBC) were lysed by RBC lysing buffer and the 
cells were resuspended in PBS at two times dilution. Flow cytometry (BD FACSCanto II 
flow cytometer) was used instead to statistically quantify tumor cells in blood.  
2.2.7 Cell regrowth after capturing 
The captured cells are bind to MPs, so they can be immobilized by magnets. To regrow the 
captured cells, place the dish containing captured cell and magnetic particle suspension on 
a magnet and remove the liquid, followed by adding HCT116 media into the dish. 
Following the cell culture protocol described before, the captured cells were cultured for 3 
passages. 
2.2.8 Clinical test 
A collaboration with a local hospital – Lehigh Valley Health Network (LVHN) Cancer 
Center was made to pursue the practicability of the CTC isolation microfluidic device on 
tumor patient blood samples. Two types of tumor patients (melanoma (MM) and Renal cell 
carcinoma (RCC)) were involved voluntarily in the project. All the patients were in stage 
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IV. Since the project will be done by the end of 2019, until now, there were 8 effective 
MM patient samples and 5 effective RCC patient samples. The antibodies used for 
capturing CTC of MM and RCC patient samples were Anti-MelanA and Anti-CA9, 
respectively. The antibodies were pre-conjugated to biotin allowing them to feasibly attach 
to MPs. Phycoerythrin (PE) labeled antibodies were used for CTC identification. Anti-
CD45-FITC was used for WBC identification. At least 3 times of repetitive flowing 
experiments were performed onto each sample to ensure a statistical significance.  
2.3 Results and discussion 
2.3.1 Magnetic particles distribution under different shear 
rates 
To obtain the highest capture efficiency, the ideal distribution of MPs in the wavy-HB 
channel is even distribution on the wavy-HB pattern, along troughs and peaks. However, 
in this work, most of the MPs would be trapped in troughs because of the magnetic force, 
and they were also subjected to shear force because of liquid flow in the narrow space. The 
images in Fig. 2.4 were taken after different concentrations of MPs injection and trapped 
by magnet. As the figure shows, at lower concentrations, the trough of the wavy pattern 
cannot be fully covered by MPs and it might indicate lower capture efficiency. The CTC 
capture experiments were also performed based on these concentrations and results are 
shown in Fig. 2.5-A. Combined with Fig. 2.4, the coverage of MPs in the trough area of 
wavy pattern is an important factor to increase capture efficiency. This is an apparent 
phenomenon that higher capture efficiency relies on higher MPs coverage. During flowing 
through the wavy chamber, the capture of CTC is determined by a collision against MPs. 
Higher coverage of MPs obviously increases the collision possibility, but while the 
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coverage is saturated (2.27 mg/mL), no remarkable capture efficiency increase compared 
to the one at 1.64 mg/mL can be observed. Actually, capture efficiency at 1.64 mg/mL is 
sufficiently high (92% ± 2.8%), so the following capturing experiments were based on this 
optimal concentration of MPs. 
 
Figure 2.4 MPs distribution in wavy-HB pattern microfluidic devices at different MPs 
concentrations: (A-D) 0.239, 0.467, 0.893, and 1.64 mg/mL. The four images share the 
same scale bar in (D). 
Groove HB pattern chips were made by the same PDMS groove pattern without the reflow 
heat treatment, and same CTC capturing experiments were performed by using these 
devices, with the results showing in the blue bar in Fig. 2.4-B.  The capture efficiency was 
only 48.1% ± 4.8% (n = 5), which was much less than the one using wavy-HB patterned 
devices. The reason is apparent because the MPs in groove pattern are gathered at the flat 
trough area by magnetic force, which has a rather low collision possibility to CTCs [76]. 
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What is more, when flow was introduced, the MPs tended to gather at downstream side 
corner of the trough, which lead to even lower collision possibility, as shown in Fig. 2.6. 
Therefore, when assisted by MPs, wavy HB pattern CTC capture devices showed great 
advantage on CTC capturing over the groove HB pattern devices. 
 
Figure 2.5 (A) HCT116 tumor cells capture efficiency by wavy-HB pattern microfluidic 
devices based on different concentrations of MPs (n = 5). (B) is the capture efficiency 
comparison of wavy-HB pattern device, flat device, groove-HB pattern device and flipped 
wavy-HB pattern device with flat bottom (n = 5). One way ANOVA statistical analysis 
with Tukey equal variances assumed, along with tests of homogeneity of variance verified 
by Brown–Forsythe and Welch analyses, performed by OriginLab 8.5. Statistical 
significance indicated by * brackets in both plots at p < 0.05. Sample collection was carried 
out from 5 independent microfluidic devices (biological replicates). All statistical tests 
have been justified as appropriate. 
 
 
 
22 
 
 
Figure 2.6 (A) typical microscope image of groove HB pattern, (B) MPs stabilized in 
groove HB pattern device and (C) MPs subjected to flow in groove HB pattern device. 
The distribution of MPs in wavy chamber does not always keep the same. In the narrow 
chamber, the MPs are exposed to two main forces—the magnetic force and the shear force. 
Magnetic force keeps them staying in the trough and static, while the shear force pushes 
them turn over the peaks and enrich them at the corner of V-shaped troughs. ImageJ was 
used to determine the total amount of MPs before and after flowing. Since MPs would be 
enriched when subjected to large flow rate, a lower concentration of MPs was used 0.893 
mg/mL in order to verify the total amount of particles, and in this case, MPs cannot be 
enriched to form an obvious stacking to affect the ImageJ counting. Fig. 2.7 shows the 
distribution of MPs after subjected to different flow rates, and the total amount of MPs 
change in a single V-shaped trough. As shown in the Fig. 2.7-B and C, at lower flow rate, 
no remarkable MPs distribution difference can be observed, but at higher flow rate, obvious 
enrichment at the corner are of the V-shaped trough can be seen. This is because when 
subjected to flow rate, MPs may be moved as long as the shear force is larger than the 
friction created by magnetic force, but most of them can only roll along the trough, because 
the magnetic force is strong enough to keep MPs as close as possible. MPs counting data 
(Fig. 2.7-F) also supports the idea that most of MPs can be retained in tough area at lower 
flow rate, but as flow rate goes higher, some portion of the MPs would be flushed away 
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from the trough, since some of them are subjected to high enough shear force and they can 
break away from the magnetic force. Actually, for 0.5 mL/h flow rate, a 1-hour PBS flow 
experiment was performed to verify the idea, and it turned out 99.8% of the MPs still stayed 
in the trough. When flat chamber without wavy pattern was used to perform the same 
experiments, most of the MPs were enriched at the outlet because they can be easily flushed 
by liquid flow, same as the flipped wavy chambers, and as a result, very low capture 
efficiency was obtained for these two control devices (Fig. 2.5-B) 
 
Figure 2.7 MPs (0.893 mg/mL) distribution after different flow rates of PBS flow. The 
flow rate used in (A-E) are the original, 0.5, 1, 2, 4 mL/h, respectively. (F) is the MPs found 
in the same trough after PBS flow. The flow volume of PBS is same for each flow rate, 
which means larger flow rate costs less time. The microscope images share the same scale 
bar in (A). 
To show the advantages of the wavy HB pattern, a comparison to groove HB patterned 
device was also made. Groove HB pattern chips were made by the same PDMS groove 
pattern without heat treatment, and same CTC capturing experiments were performed by 
using these devices, with the results showing in the blue bar in Fig. 2.5-B. The capture 
24 
 
efficiency was only 48.1%±4.8% (n = 5), which was much less than the one using wavy-
HB patterned devices. The reason is apparent because the MPs in groove pattern are 
immobilized at the flat trough area by magnetic force, which has a rather low collision 
possibility to CTCs [76]. What is more, when flow was introduced, the MPs tended to 
gather at downstream side corner of the trough, which lead to even lower collision 
possibility between CTC and MPs, as shown in Fig. 2.6. 
2.3.2 Effect of flow rate during cell suspension injection 
The flow rate during cell suspension injection for capturing is much lower than during PBS 
clearance for surplus non-bind antibodies, so in these flow rate conditions, the distribution 
of MPs would not have an apparent change. As shown in Fig. 2.8, the flow rate during cell 
suspension injection dramatically affects the capture efficiency, and expressed in brief, the 
lower flow rate, the higher capture efficiency. This is reasonable as described in the above 
section: the capture efficiency is a function of the positive factor of binding between CTC 
and antibodies on MPs and the negative factor of separation formed by shear rate. What is 
more, the lower shear rate results in higher binding success rate when antigens colliding 
against antibodies [76]. However, the lower is the flow rate, such as 135 µL/h, even though 
extremely high capture efficiency can be obtained (96.3% ± 1.2%), the longer would be 
the time that is needed for capturing CTC in certain volume of cells, so it should choose a 
balance between capture efficiency and running time. As shown in Fig. 2.8, the flow rate 
of 540 µL/h (with capture efficiency of 92% ± 2.8%) is a good choice for following 
experiments. 
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Figure 2.8 Effect of cell injection flow rate on capture efficiency (* means P < 0.05, 1-
way ANOVA and Tukey post-hoc test).  
2.3.3 Effect of Anti-EpCAM concentration 
The distribution of antibodies on MPs is another key factor for enhancing capture 
efficiency. The MPs used in this study were pre-coated streptavidin, and since anti-EpCAM 
conjugated with biotin had a strong binding with streptavidin [77], the volume of anti-
EpCAM used in mixing antibody coated MPs determines its coverage. The best condition 
is MPs are fully or saturatedly coated with antibodies. Four different concentrations of anti-
EpCAM were used to react with MPs and from the capture experiments results, as shown 
in Fig. 2.9, 8 µg/mL of the original solution is the best choice to give high capture 
efficiency. 
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Figure 2.9 Effect of anti-EpCAM concentration on capture efficiency (* means P < 0.05, 
1-way ANOVA and Tukey post-hoc test). 
2.3.4 Capture sparse CTC 
Before dealing with the real blood samples, the capability of capture sparsely distributed 
CTC is rather significant, for that the CTC concentration is rather low in real blood samples 
(one to a few hundred in 1 mL blood) [46], [75]. Six different CTC concentrations, as lower 
as 200/mL (50 µL suspension was flowed, resulting about 10 CTCs), were used to perform 
capture experiments, and about 80-90% capture efficiency were obtained, as shown in Fig. 
2.10. This indicates that the method is capable of efficiently capturing CTCs even when 
the total cell amount is as less as ten levels. To show reliability of the device on larger 
sample volume, we also performed CTC capturing experiments on 2 mL 20/mL cell 
suspension. The capture efficiency was still high (83.7%±7.8%, n=3). 
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Figure 2.10 Capture efficiency when dealing with low concentration of HCT116 cells. The 
lowest HCT116 cell concentration is 200/mL (50 µL suspension was flowed, resulting 
about 10 CTCs). With 1-way ANOVA and Tukey post-hoc test, no significant difference 
were found between different cell concentrations. 
2.3.5 CTC capturing from whole blood using flow cytometer 
Flow cytometry is an effective cell-quantification method to deal with cell samples in large 
quantity. To determine the capture efficiency of tumor cells in whole blood, flow cytometry 
was used. Using all the optimized experimental conditions (flow rate during cell injection 
= 540 µL/h, magnetic particle concentration = 1.64 mg/mL, antibody concentration = 8 
µg/mL), CTC capturing from whole blood on the HB-wavy microfluidic device was 
performed. Tumor cells were firstly stained with CellTracker Green, and mixed with whole 
blood to obtain tumor cell suspension in whole blood with different concentrations, as low 
as 100/mL. Although an addition of droplet of tumor cell suspension diluted the whole 
blood, the dilution ratio was usually only 1:100, so we still treat the mixture as whole blood 
sample. Since the tumor cells were the only fluorescent cells, they could be easily identified 
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by either fluorescence microscope or flow cytometer. To eliminate or reduce the 
interference of red blood cells, RBC lysing buffer was used to remove most of the RBCs 
in the collected tumor cell suspension. When dealing with higher concentrations (500, 1000, 
2000, 5000/mL), the flow cytometer was rather effective, as black dots shown in Fig. 2.11. 
However, when the concentration went lower to 200 and 100/mL, flow cytometer could 
not collect enough events to prove the consistency, especially for the uncaptured tumor 
cells, so for these two cases, manual counting under a fluorescence microscope was used 
to determine the capture efficiency, as blue dots shown in Fig. 2.11. As the capture 
efficiency result in whole blood shown in Fig. 2.11, the device could collect most HCT116 
cells from whole blood, even when the tumor cell concentration was as low as 100/mL 
(capture efficiency = 81.5% ± 12.0%). Manual counting was also performed on 500/mL, 
and the obtained capture efficiency was 94.4% ± 3.2%, which showed a good consistency 
with flow cytometer counting on the same cell concentration (95.3% ± 2.8%), as shown in 
the two 500/mL points in Fig. 2.11.  The purity or selectivity of captured CTCs could be 
obtained from flow cytometry. As shown in Fig. 2.12, the events in red showed the pre-
stained tumor cells and other events that happened in the same range as the tumor cells 
were marked out and counted. These events were treated as impurities, which might include 
white blood cells, macrophages, and MPs clusters. The purity of captured CTCs was 91.3% 
± 1.2% (n=3). Actually the purity could be even higher because the impurities might have 
non-cell components, such as MPs clusters. 
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Figure 2.11 Capture efficiency from whole blood samples based on different tumor cell 
concentrations. (Black dots) Data obtained from flow cytometer, and (Blue dots) data 
obtained from manual counting. With 1-way ANOVA and Tukey post-hoc test, no 
significant difference were found between different cell concentrations. 
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Figure 2.12 Flow cytometry results to show the selectivity of the CTC capture device. The 
events (red dots) showed the pre-stained tumor cells. Other events (black dots) that 
happened in the same range as the tumor cells outlined by red lines were counted, and these 
events were treated as impurities, which might include white blood cells, macrophages, 
and MPs clusters. The purity or selectivity was obtained by  
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
# 𝑜𝑓 𝑐𝑎𝑝𝑡𝑢𝑟𝑒𝑑 𝑡𝑢𝑚𝑜𝑟 𝑐𝑒𝑙𝑙𝑠
# 𝑜𝑓 𝑐𝑎𝑝𝑡𝑢𝑟𝑒𝑑 𝑡𝑢𝑚𝑜𝑟 𝑐𝑒𝑙𝑙𝑠 + # 𝑜𝑓 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑖𝑒𝑠
 
 
2.3.6 Regrowth of captured cells 
The feasibility of re-culture of collected cancer cells was also investigated. The captured 
tumor cell sample containing both collected tumor cells and MPs were cultured in a regular 
petri-dish. One day after the initial sample loading, both tumor cells and MPs were settled 
down on the petri dish, as shown in Figure 2.13 (a). To observe the attached MPs change 
over the course of cell proliferation, a series of microscopic images continuously recorded, 
from day 1 to day 4, and then from passage 0 to passage 2, as shown in Figure 2.13 (b-d). 
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During medium change, most of the un-attached MPs could be washed away, as shown in 
Fig. 2.13 (b), which shows the day 4 of passage 0, but most of MPs that attached to cells 
were remained, with less density. This can be explained that during proliferation, more 
cells generated more cell membrane and made the MPs density lower. However, it was 
interestingly found that the density of MPs on cells even gradually disappeared during cell 
splitting as shown in Fig. 2.13 (c) and (d), after two passages, MPs can barely be found on 
tumor cells. The exact mechanism was still unclear, but one possible reason is the total cell 
membrane area increases as the cell population increases, so the density of MPs decreases; 
and another possible reason is naturally deactivation of anti-EpCAM and EpCAM on cell 
membrane, either of which loses function would cause MPs falling off CTCs. 
Cells that were just captured were concentrated by centrifuge and a dead/live assay was 
performed, and the result was shown in Fig. 2.13-e.  The viability was 94.1% ± 2.3% (n=3), 
indicating the MPs assisted capture and release had negligible negative effect on viability. 
The long term viability of these captured cells was also considered. As shown in Fig. 2.13-
f, after 12 h incubation, the captured cells started to spread on petri dishes, and some of 
them even started proliferating. The viability at 12 h, 24 h, 48 h, 96 h incubation were over 
95%. What was more, over 50% of the captured cells doubled due to mitosis within 36 h 
(at cell density of about 100 in a well of 96 well plate), similar to the original cells. These 
all indicated that there was no remarkable long term negative effect on the captured cells. 
Additionally, there are plenty of researches on MPs assisted CTC isolation, and no 
remarkable negative effect on gene expression and phenotype could be found [78]–[81]. 
 
32 
 
 
Figure 2.13 Re-culture of captured HCT116 cell sample. The sample had both captured 
HCT116 cells with MPs and individual MPs. (a)-(b) Cell re-culture on Day 1 and Day 4 
for Passage 0, respectively. (c)-(d) Cell re-culture for Passage1 and Passage 2, respectively. 
(e) Dead/Live staining images of captured HCT116 cells just after captured. Cells were 
linked because bare cell membrane attached to MPs on other cells during centrifuge. (f) 
Dead/Live staining images of captured HCT116 cells after 12 h incubation in petri dish. 
All the scale bars are 40 μm. And (a-d) share the same scale bar. As a collaborator of the 
project, Dr. Shunqiang Wang kindly provided figure (a-d), which were also shown in his 
dissertation. [26] 
2.3.7 Clinical test 
Two types of cancer patient samples (RCC and MM) were tested using our device and the 
quantitative capture results of were shown in Fig. 2.14. The CTC counts were obtained 
from flowing 2 mL of blood sample into the device. Since all these samples were from 
patients with stage IV cancers, most of them showed existence of CTCs. The sample RCC-
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02 was from a fully-cured patient, and no CTC was found in this sample. There was a large 
variance among the MM samples, and the more CTC count samples represented severe 
situations for the patients. Anti-CD45 did not show remarkable distinguishing ability on 
WBCs, so another method was used for CTC identification, as shown in Table 2.1. Typical 
fluorescence images of the captured CTCs and WBC can be found in the lower figure of 
Fig. 2.14. Since there was no other effective way that enabled evaluation of the capture 
results, we ran additional flow experiment on the concentrated passing-through samples, 
and almost no CTC could be found in the second round of experiments. This, in certain 
means, proved that the device was able to isolate most of the CTCs out of whole blood 
samples. Besides knowing the number or concentration of the CTC in blood samples 
(enumeration), another goal of the project was to obtain the CTCs and perform post-
analyses on them, such as single-cell sequencing, regrowth, etc. However, due to the 
complexity of the patient blood samples, WBCs in these samples were able to bind to MPs 
and a large quantity of WBCs were captured by the device (>100 each time). This 
precluded us to collect the captured CTCs for other applications. More work should be 
done to understand why WBCs bind to MPs, and another method that might solve this 
problem is presented in the next chapter. 
Table 2.1 Identification of MM CTC, RCC CTC, and WBC from patient samples. 
Cell Type DAPI Calcein AM MelanA CA9 
MM + + + N/A 
RCC + + N/A + 
WBC + + - - 
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Figure 2.14 CTC enumeration results from tumor patient samples. (Upper) Quantitative 
results from 8 MM patient samples and 6 RCC patient samples. (Lower) Typical 
fluorescent images of CTCs and WBC from patient samples. 
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2.4 Conclusions 
Immunoaffinity and magnetic force were used in a wavy-HB structured microfluidic 
device to effectively and selectively capture and release CTCs. Due to the pattern in 
the that creates passive turbulence and increases the possibility of tumor cells 
colliding to the device wall, the device was rather effective on capturing tumor cells, 
either in pure cell suspension or in patient whole blood samples. The device with 
this method can be potentially used for CTCs sorting from patient blood samples, 
CTCs concentration monitoring, therapeutic guidance and drug dosage choice, and 
further study of tumors, such as drug screening and tumor mutations. The device 
was used for isolation of CTCs from real tumor patient blood samples. 
 
 
  
36 
 
Chapter 3:   Isolation of white blood 
cells, circulating tumor cells, and 
circulating tumor cell clusters on the 
same microfluidic device by 
centrifugal force 
3.1 Introduction 
As mentioned in Chapter 2, the liquid biopsy method for tumor cells demonstrates high 
efficiency and convenience over tissue biopsy, which is technically complicated and 
burdensome for patients [82]. Liquid biopsy can be executed routinely, as taking patient 
blood samples is a simple process. However, using liquid biopsy for CTC identification 
and collection is a daunting task, as separating CTCs from blood is difficult due to the 
CTCs’ rarity in blood (~1-100 CTCs per 109 blood cells), variety of chemical properties, 
and diverse morphologies [57]. To distinguish CTC from massive blood cells, typically 
two differentiating characteristics of CTCs are utilized. CTCs typically have unique surface 
identity proteins [83]–[87], such as EpCAM used in Chapter 2, which other blood cells do 
not express on their surfaces. Another differentiating quality is that CTCs are typically 
larger than blood cells [88], [89]. Existing methods for CTC-blood separation utilize these 
two characteristics of CTCs, i.e. affinity binding methods using surface antigens and size-
based separation techniques. Chapter 2 introduced a method which utilized the surface 
antigens of CTCs, showing a good isolation efficiency of CTCs. However, due to the 
complexity of the patient blood samples, large amounts of white blood cells (WBC) can 
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also be captured by the device, which precluded the possibility of collecting the captured 
CTCs for other applications. 
In most cases, metastasis cells are individual and singular in the circulatory system. 
However, sometimes two or more clustered tumor cells migrate from the original tumor 
site and enter into the circulatory system. These types of cell bundles are typically referred 
to as circulating tumor cell clusters (CTCC) [90]–[92]. Although not prevalently abundant 
in tumor patient blood, they are deemed to be more invasive than single CTCs [93]. 
However, further studies were stagnant for decades due to limitations of CTCC isolation 
in humans. Despite recent advances in CTCs isolation [24], [94], [95], very limited 
progress has been achieved in CTCC isolation. For example, researchers have already 
identified that CTCCs are heterogeneous, with certain subgroups of CTCCs harboring 
higher metastatic potential [45], [96], [97]. The capture and analysis of CTCCs offers new 
insight into tumor metastasis and can facilitate the development of cancer treatments. The 
prevalence and quantity of CTCCs can be underestimated due to their short detection 
window and lack of appropriate detection methods. The lifespan (existence in the 
circulatory system) of CTCC is usually short (a few hours) [98], and can be split in small 
blood vessels due to their large size. On the other hand, a very limited number of effective 
devices have been designed with the focus of CTCC detection and isolation. The isolation 
of CTCC is still performed using the two aforementioned principles for CTC isolation: 
difference of surface proteins [99]–[101] and difference of size [63], [102]–[105]. 
Compared to using difference of surface proteins, the size difference between CTCC and 
other types of cells (including CTC) is much more dramatic. As a result, more research 
regarding CTCC capture or isolation was focused on using the size difference, such as 
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physical filtering [54] and centrifugal force [57]. In most cases, the capture of isolation of 
CTCC were by-products of CTC isolation [57]. Therefore, a new method that can be used 
for isolation of pure CTCC is needed. 
Fluid usually flows through a straight tube in a laminar fashion, while fluid flows more 
turbulently through a curved tube. Such turbulent flow patterns, coupled with centrifugal 
acceleration in a radial direction, result in two equal counter-rotating vortices (on the top 
and bottom) which rotate along the channel’s cross-section. These are referred to as Dean 
vortices, and the magnitude of these flows are quantified by a dimensionless Dean number 
(De) [106]. A schematic illustration of Dean vortices can be seen in Fig. 3.1, and the De 
Equation is: 
𝐷𝑒 = 𝑅𝑒√
𝐷
2𝑅𝑐
 
Where Re is the Reynolds number, D is the diameter (for rectangular channels, an 
equivalent diameter is usually used), and Rc is the radius of curvature of the path of the 
channel. For a given microfluidic channel, both D and Rc are constant, so De is directly 
proportional to Re, which is defined by: 
𝑅𝑒 =  
𝑢𝐿
𝜈
 
Where u is the velocity of the fluid with respect to the object (m/s), L is a characteristic 
linear dimension (m), and ν is the kinematic viscosity of the fluid (m2/s) [107]. If ν is 
assumed to be constant, both Re and De is directly proportional to the flow rate of the liquid 
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that is introduced to the curved channel. Therefore, simply tuning the flow rate can change 
the Dean number, and thus regulate the Dean vortices. 
 
Figure 3.1 Illustration of Dean vortices in a curved rectangular channel. 
When liquid flows with particles into a curved channel, Lateral Dean drag forces (FD) drive 
particles along the direction of the Dean vortices, causing particles to move between the 
inner and outer walls along the width of the channel [107]. This lateral movement, where 
the particle begins near the outer wall of the channel and moves to the inner wall, then back 
to the outer wall, is called a full Dean cycle [57]. Larger particles also experience inertial 
lift forces (FL) near the inner wall, therefore causing larger particles to take longer to 
complete a full DC [108]. Thus, as a blood sample travels through some channel, the CTCs, 
CTCCs, and WBCs in the sample flow along the Dean vortex and migrate toward the inner 
part of the channel. Near the inner wall, the larger CTCs and CTCCs focus tightly as they 
experience strong FL’s which prevent them from moving further under influence of the FD. 
The smaller WBCs, however, continue to flow along the Dean vortices and travel back 
towards the outer wall of the channel. For high-throughput CTC and CTCC isolation, a 
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microfluidic spiral channel design will be used for the study, where the blood sample can 
be pumped through one inlet and sheath fluid (PBS) through the other inlet. This allows 
for the continuous collection of CTC and CTCC (which migrate to the inner wall) at the 
inner smaller outlet, with WBC (which migrate toward the outer wall) discarded from the 
outer larger outlet. 
A device that utilizes the Dean vortices created by curved microfluidic channels would 
allow the isolation of CTC and CTCC from blood samples. The three cell types (plus 
WBCs) show distinct size differences (CTCC, usually larger than 20 µm; CTC, 20 µm ~ 
10 µm; and WBC, 12 µm ~ 7 µm ) [109]–[111]. Although there is overlap in the size of 
CTCs and WBCs, most of the WBCs are smaller than 12 µm, while the size of CTCs is 
usually centered at 13-15 µm. Therefore, a two-step process was designed to isolate CTCCs, 
CTCs and WBCs. The high quantities of red blood cells (RBCs) could be removed by RBC 
lysing. By tuning the flow rate, which controls De if other conditions are fixed in the same 
spiral channel, the Dean flow can be tuned to isolate different sizes of cells. In our 
observation, slower flow rates allowed for efficient isolation of smaller cells, and vice versa. 
3.2 Experimental 
3.2.1 Spiral microchannel design 
The microchannel design consists of a 2-inlet, 2-outlet spiral microchannel, as shown in 
Fig. 3.2. The channel width is 500 µm and has a height of 150 µm. The two inlets were 
125 µm and 375 µm wide, with the smaller one for sample injection and the larger one 
for buffer sheath to increase the flow rate. A semi-circle channel is linked to inlets with 
Rc = 5 mm, with a spiral channel linked to the other end. The start Rc of the spiral 
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channel is 10 mm, with the increase of Rc = 1 mm/circle. For example, a spiral channel 
that goes through 1.5 circles would have an end Rc = (10 + 1.5) mm. The two outlets 
were set to be 400 and 100 µm wide. The microchannels vary only in the length of the 
spiral channels, so we use the length of the spiral channel to name them. For example, 
the spiral channel that goes through 1.5 circles would be named “1.5 spiral channel”. 
 
Figure 3.2 Illustration of the dimension of the 1.5 spiral channel. 
3.2.2 Fabrication 
Soft lithography was used to fabricate the devices. In brief, as shown in Fig. 3.3, the 
designed spiral structures with inlets and outlets were saved in a .pdf file and printed to 
become photo masks by CAD/Art Inc. (Bandon, Oregon). SU8 was used as the photoresist 
and lithography was performed to from silicon templates. PDMS (Sylgard 184, base and 
curing agent were mixed in a 10:1 ratio) pieces were replicated from the template. After 
which the inlets and outlets were made using a punch to remove material. The PDMS 
replicates were attached to glass slides by oxygen plasma treatment. Since the devices 
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usually experience high liquid pressures during use, the bond between the PDMS and glass 
needed to be extremely firm, which requires high degree of cleanliness for both materials 
and thorough oxygen plasma treatment. 
   
Figure 3.3 Standard soft lithography for fabrication of the spiral microfluidic device. 
3.2.3 Flow experiments setup 
The channels were first wet and incubated with 1% BSA to reduce cell attachment. All the 
inlets and outlets were connected to soft tubing, which were connected to syringe pumps 
and collection containers, respectively. A series of flow rates were used to obtain the 
optimal experimental conditions. The flow rate ratio of the sheath to the sample was always 
set at 9:1 to ensure a high flow rate and thus high De, as well as a high dilution of the 
samples. To balance the liquid pressure, the sheath was pumped through the device first, 
and when the flow stabilized, the sample was injected. All the liquid from both outlets were 
collected and could be used for other experiments. 
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3.2.4 Cell lines and man-made clusters 
The human colorectal cancer cell line, HCT116, was used as a model CTC in this work. 
Interestingly, this cell line can easily form single cell suspensions or cluster suspensions 
by adjusting the trypsin treatment time. Insufficient trypsin treatment would lead to the 
preservation of some cell-cell junctions, thus plenty of clusters would form. The cells were 
cultured in 5% CO2 and at 37 °C, and incubated with DMEM supplemented with 10% FBS 
and 1% Antibiotic & Antimycotic. The medium was changed every 2 days. When the cells 
reached 80-90% confluency, they were subcultured and 0.05% Trypsin - 0.53 mM EDTA 
was used for cell detachment. To obtain a single cell suspension, 6 min of trypsin treatment 
and several cycles of vigorous pipetting was necessary. To obtain CTCC suspension, a 3 
min of trypsin treatment was required with gentle handling of the clusters. Usually CTCCs 
with 2-20 tumor cells were obtained. Both types of cell suspensions were pre-stained with 
CellTracker Red. 
WBC used for flow experiments were obtained from whole blood with RBC lysing. In 
brief, 1 mL whole blood was combined with 20 mL of RBC lysing buffer (ThermoFisher), 
followed by a 30-min incubation in the dark at room temperature.  The mixture was then 
centrifuged at 500 g for 5 min. The supernatant was discarded, and the pellet was washed 
for 2-3 times with PBS. WBCs were pre-stained with CellTracker Green before use. 
3.3 Results and Discussion 
3.3.1 Optimization of the spiral device 
1.75 spiral channels were tested first. An RBC suspension was used as a model sample, 
and PBS was used as a sheath fluid. RBCs closely mimicked WBCs and facilitated 
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observation. Different flow rates (from 5 + 45 mL/h to 18 + 162 mL/h, with 1 + 9 mL/h 
being used as an incremental step between cases. The lower flow rates were for sample 
injection, while the higher flow rates were for sheath injection) were tried. Interestingly, 
all of the flow rates tested, the RBCs came out from the smaller (inner) outlets. At lower 
flow rates (< 14 + 126 mL/h), after running through the half circle channels, RBCs flipped 
from the outer wall to the inner wall and remained along the inner wall until the end of 
channels. There was a transition between 15 + 135 mL/h and 16 + 144 mL/h, as shown in 
Fig. 3.4. No clear Dean cycle could be observed in Fig. 3.4-A, which shows the flow rate 
of 15 + 135 mL/h. However, a clear Dean cycle (indicated by a yellow arrow) was finished 
at the yellow arrow in Fig. 3.3-B, which shows the flow rate of 16 + 144 mL/h, after which 
another half Dean cycle was completed. Because the RBCs stuck along the inner wall and 
exited from the inner outlet at large range of flow rate, it seemed as though it was hard to 
use such a device to isolate different sizes of cells. As we observes the RBC position change 
within the channel, shortening the channels was attempted to realize the goal of isolation. 
Therefore, 1.5 spiral channels were tested second. 
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Figure 3.4 Illustration of particle locations in 1.75 spiral channels at different flow rates. 
Red lines shown in the channel indicate particle locations. Since the particles were 
introduced from the sample inlets, they were present on the outer wall side of the spiral 
channels initially, however after running through the semi-circle channel (which gives the 
flow a very high De), they were transported to the inner wall side by Dean vortices. This 
indicated that the flow finished a half Dean cycle. The flow rate between 15 + 135 mL/h 
and 16 + 144 mL/h were also tested (C and D), which also showed that RBC exited from 
the inner outlet. 
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Figure 3.5 Particle location in the outlet area of 1.5 spiral channels at different flow rates. 
The numbers underneath each image indicate the two flow rates (mL/h) which were used 
in sample inlet and sheath inlet, respectively. At flow rates of 9 + 81 mL/h to 13 + 117 
mL/h, the majority of the particles exited from the larger outlet, which indicated that the 
flow finished one full Dean cycle. The three spiral channel figures show the typical particle 
locations in the channel at different flow rates. 
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The same settings were used in the trials with the 1.5 spiral channels, and the results are 
shown in Fig. 3.5 with only the outlet area displayed in the figure. At lower flow rates (less 
than 8 + 72 mL/h), the RBCs finished a half Dean cycle after running through the half 
circle channel and remained along the inner wall in the spiral channel. This indicated that 
almost no Dean flow was occurring in the spiral channel, while at high flow rates (higher 
than 14 + 126 mL/h), the flow was able to complete more than one Dean cycle. At flow 
rates of 9 + 81 mL/h to 13 + 117 mL/h, the majority of the particles exited from the larger 
outlet. As shown in the spiral structure in Fig. 3.2, the larger outlet is on the outer side of 
the spiral channel. The particles being localized on the outer side indicates that the flow 
completed a Dean cycle, since the particles were introduced on the outer side. Therefore, 
by tuning flow rate, the 1.5 spiral channel was able to allow the particles (RBC) in flow to 
flip back and force in the channel. The following experiments were completed using this 
type of microfluidic device. 
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Figure 3.6 Fluorescent images of cells exiting from the two outlets of the 1.5 spiral 
channels at different flow rates after being initially well mixed. WBCs were pre-stained 
with Calcein AM and HCT116 single cells and clusters were pre-stained by CellTracker 
Red. 
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Figure 3.7 Quantitative estimation of relative cell counts from the two outlets of the 1.5 
spiral channels at different flow rates. 
WBCs were obtained from RBC lysing of a blood sample, and pre-stained with Calcein 
AM, which displays green fluorescence. Single tumor cell suspensions and cluster tumor 
cell suspensions were pre-stained with CellTracker Red, which displays red fluorescence. 
The three cell types were mixed well before use. A series of flow rates were used, from 7 
+ 63 mL/h to 12 + 108 mL/h. The cells from both the outlets were collected and the results 
are shown in Fig. 3.6 and 3.7. Fig. 3.6 shows typical fluorescent images of the cells out of 
the 1.5 spiral channels at different flow rates, while Fig. 3.7 shows the quantitative 
estimation of the three types of cells from the two outlets of the spiral channels at different 
flow rates, respectively. Interestingly, at lower flow rates (such as 8 + 72 mL/h), most of 
the WBCs exited from the small outlet and tumor cells exited from the large outlet, while 
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at higher flow rate (such as 12 + 108 mL/h), most of the single tumor cells emerged from 
the small outlet and most of the cluster tumor cells emerged from the large outlet. This 
interesting phenomenon is explained in Fig. 3.8. In blood fractionation, during 
centrifugation, smaller cells such as RBCs settle down earlier than larger cells such as 
WBCs. Since cells experience a similar centrifugal force when introduced into the spiral 
channels at relatively high flow rates, the smaller cells would follow the Dean vortices 
further than larger ones. As shown in Fig. 3.4, when the flow rate was higher than 8 + 72 
mL/h, the particles finished a Dean cycle in the device. At 8 + 72 mL/h, the larger cells 
(CTC and CTCC) exited from the larger outlet, which means they finished a full Dean 
cycle, while the smaller cells (WBCs) completed more than one Dean cycle (~1.5 Dean 
cycle), illustrated in Fig. 3.8-A. On the other hand, both the largest cells (CTCCs) and the 
smallest cells (WBCs) exited from the larger outlet, with the middle-sized cells (CTCs) 
exiting from the smaller outlet, as shown in Fig. 3.8-B. This can be explained by the CTCs 
completed 1.5 Dean cycles, while WBCs completed 2 Dean cycles, which caused the 
WBCs to exit from the larger outlet. The CTCCs were still in the one Dean cycle range and 
exited from the larger outlet. This phenomenon led to a promising experimental hypothesis 
that a 2-step method could be effective in isolating these three types of cells. 
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3.3.2 2-step method 
 
Figure 3.8 Illustration of motion trail for CTCC (green line), CTC (blue line) and WBC 
(yellow line) in the spiral channels at lower and higher flow rates. For better visualization, 
straight channels were used. 
The working principle of the 2-step isolation method is illustrated in Fig. 3.9. In step 1, a 
slower flow rate would be used to process samples which were mixtures of WBCs, CTCs 
and CTCCs. By choosing the optimal flow rate, the WBCs being the smallest cells among 
the three could be precluded from the small outlet, while the large outlet collected the 
mixture of CTCs and CTCCs. Followed by a step to concentrate the mixture, step 2 utilizes 
a higher flow rate for separation of CTC and CTCC.  Most CTCs exit from the small outlet 
while CTCCs were collected from the large outlet. In the following experiments, the low 
flow rate in step 1 was set to be 8 + 72 mL/h, while 12 + 108 mL/h was selected as the high 
flow rate in step 2, both of which showed the most distinct separation in Fig. 3.6. 
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Figure 3.9 Illustration of the 2-step method for WBC, CTC and CTCC isolation using the 
spiral channels. 
 
Figure 3.10 Typical fluorescence images of the cells collected from both outlets. The left 
two images were cells collected in step 1 experiments; the right two images show the cells 
collected in step 2. Except for the small outlet in step 1, all other three samples were 
concentrated and put into a well of 96 well plate to show better visual results because the 
cells were highly concentrated. All four of the images share the scale bar in left upper. 
To demonstrate the idea, relatively high initial CTCC and CTC concentrations were used 
first. Specifically, a 5 mL sample was loaded with 1000 CTCCs, 1000 CTCs, and 50,000 
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WBCs. In step 1, for which the flow rate was 8 + 72 mL/h, cell suspensions from both 
outlets were collected, and the one from the large outlet were concentrated by 
centrifugation and resuspended in 5 mL of PBS buffer, which was used as the sample for 
step 2. With a flow rate of 12 + 108 mL/h, liquid from both outlets was collected and 
concentrated to 200 µL and put into wells in a 96 well plate for better visualization. The 
results are shown in Fig. 3.10. Obviously, although the quantity of WBCs was 50 times 
greater than that of the CTCs and CTCCs, due to the size difference and Dean vortices, 
most of them exited from the small outlet in step 1, with negligible amounts exiting from 
the large outlet. So in this step, the WBCs were nearly removed. In step 2, as the flow rate 
increased, the device enabled isolation of CTCs and CTCCs exiting separately from the 
two outlets. Quantitative characterization was not performed in this experiment, because 
the used concentrations were not physiologically relevant. A more physiologically relevant 
experiment will be performed next. 
To better mimic physiological conditions (the physiological ratio of CTC to WBC is in the 
range of 1:105 to 1:107), a 5 mL sample loaded with 10 CTCCs, 100 CTCs, and 1,000,000 
WBCs was used, and the quantitative results are shown in Fig. 3.11. The statistical data 
was obtained from 3 repeated experiments. As the results suggest, the isolation of the three 
cells types was efficient. The mean isolation efficiency was defined as: 
Isolation Efficiency =
Cell counts from the major outlet
Cell counts from both outlets
 
The isolation efficiencies for CTC and CTCC after the 2 steps were 86.7% ± 2.8% and 93% 
± 6.3%, respectively. The isolation ratio of WBC out of small outlet to large outlet in step 
1 was higher than 500:1. Relatively pure CTCs and CTCCs could be obtained in step 2, 
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with limited WBCs in the samples, as shown in Fig. 3.11. Therefore, although the amount 
of WBC was 10,000 times and 100,000 times greater than the CTCs and CTCCs, 
respectively, the spiral device was still able to isolate the three types of cells. 
During the flow experiments, CTCs and CTCCs experienced a relatively high shear force, 
the feasibility of regrowth of the isolated CTCs and CTCCs was also investigated. Most of 
the captured cells were able to attach to petri dishes and proliferate, which means the cells 
were not affected during the flow experiments. 
 
Figure 3.11 Quantitative results of the 2-step flow experiment performed on a 5 mL sample 
loaded with 10 CTCC, 100 CTC, and 1,000,000 WBC. The WBC from small outlet in left 
figure was more than 100,000, which was much more than other values in the figure, so it 
is not accurately shown in the figure. (* means P < 0.05, 1-way ANOVA and Tukey post-
hoc test). 
3.4 Conclusions 
Centrifugal force was introduced by using spiral channels in microfluidic conditions for 
isolation of three cell types WBC, CTC, and CTCC. Due to the size difference among these 
cells, they experienced different centrifugal forces when flowing through the microfluidic 
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device, enabling them to exit from different outlets of the device. At lower flow rates, 
WBCs could first be isolated, with CTCs and CTCCs being isolated at a higher flow rate. 
The device coupled with the method described above has the potential to be used for 
isolation of CTCs and CTCCs from patient blood samples, CTC concentration 
monitoring, therapeutic guidance and drug dosage selection, and further tumor 
studies, such as drug screening and tumor mutations. A clinic trial conducted in 
collaboration with the Lehigh Valley Health Network (LVHN) Cancer Center is 
underway to test the applicability of the device for the isolation of CTCC and CTC 
from renal cell cancer patient blood. 
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Chapter 4:  Facile Tumor Spheroids 
Formation in Large Quantity with 
Controllable Size and High Uniformity 
 
4.1 Introduction 
Advancements in cell culture techniques have shown that there are many important 
advantages of three-dimensional (3D) cell culture systems. Compared to two-dimensional 
(2D) cell monolayers, 3D models more accurately mimic the complex in vivo 
microenvironment and produce cellular behavior more close to natural conditions [112]–
[115]. For cancer drug screening applications, traditional 2D cell cultures may be more 
convenient, but they do not adequately reproduce the complexity of in vivo tumor tissue 
and their interactions with extracellular matrix (ECM) components. Specifically, the 2D 
monolayers face morphological limitations and an absence of cell-cell and cell-ECM 
interactions [116]–[119]. Consequently, loss of tissue-specific properties is common for 
cells in 2D monolayer cultures [120]. Research shows that 3D cultures are more relevant 
in terms of tumor cell responses to microenvironmental signals, including growth factors, 
cell-cell interactions, ECM molecules, nutrient and oxygen gradients, and gene expression 
[121]. In one study, due to alterations in gene expression, inhibition of EGRF was observed 
as less effective in colorectal cancer cells grown as 3D spheroid models compared to 2D 
cultured cells [122]. Other research also supports that phenotypic differences for spheroids 
often include higher cell viability and higher detoxification ability compared to monolayer 
cultures [120]. It is clear that there is a potential for changes in protein expression levels to 
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impact the success of drug therapies. Thus, 3D tumor models are necessary for obtaining 
realistic and clinically translatable data to bridge the gap between preclinical cell-based 
assays and subsequent drug studies. 
Sutherland et al. first recognized that multicell spheroids could be grown in tissue culture 
as models for carcinoma nodules [123]. Upon observation, it was found that the spheroids 
captured similar features of real tumors, including response to anti-cancer treatments and 
the development of an outer region of cell division gradually leading to an inner core of 
necrosis. Since then, the multicellular tumor spheroid (MCTS) has been recognized an 
excellent 3D model for cancer research and numerous protocols for spheroid formation 
have been developed. 
One of the most common techniques used is the Liquid-Overlay method, where spheroids 
are cultured in a liquid suspension over a non-adhesive surface. Agarose gel works well as 
a non-adhesive surface, as first introduced by Costachel et. al in 1969  [124], [125]. Most 
commercially available agarose preparations can be used after mixing with distilled water, 
and a suitable portion should be placed on the bottom of the well or dish and cooled to 
allow for gelling to occur. After it is completely solidified, monolayer-cultured cells can 
be seeded above the agarose.  For human cells, aggregates will form in about 2-3 days 
[125]. Benefits of this method include easy access and manipulation of the spheroids, 
uniformity, and controllable size. Yet the process yields very low quantities because only 
one spheroid is formed per well, the single cells that fail to aggregate need to be manually 
removed, and some form flat disks aggregates rather than spheroids. 
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Originally developed for cultivating stem cell embryoid bodies, the Hanging-Drop 
technique involves deposition of cell-suspension drops on the inside of a tissue culture dish 
lid [120], [126]. Droplets 10-30 L in volume are placed on the underside of the lid and 
hold around 300-3000 cells [126]. When the lid is inverted, surface tension holds the 
droplet in place. The microgravity produced by the suspension concentrates the cells at the 
liquid-air interface, and a single spheroid is formed [120]. Because it requires no 
specialized equipment, this process is very cost effective and easy to replicate. This is a 
useful method for forming MCTSs of defined and narrow size distribution, but the process 
is time-consuming, hard to manipulate, and ineffective for producing mass quantities. 
MCTSs can also be formed using external forces to concentrate suspended cells in high 
density. One example is the use of magnetic fields to promote cell aggregation and spheroid 
formation from single cells. The technique requires magnetic labeling, which can be done 
through cell internalization of magnetic particles or through immunomagnetic labeling 
[127], [128]. Immunomagnetic labeling is more effective and involves attaching anti-body 
coated particles to cell member proteins [127]. Hanging drops containing the magnetically 
labeled cells are then cultured, and the spheroids formed can then be easily separated by 
applying a magnetic field [129]. Spheroids produced using this method showed similar 
protein expression profiles as some human tumors [128]. Though magnetic levitation is 
relatively easy to replicate, it produces spheroids of poor uniformity and uncontrollable 
size.  
Another method involving suspensions utilizes bioreactors developed by the National 
Aeronautics and Space Administration (NASA). The bioreactors, also referred to as HARV 
(high aspect ratio vessel), are designed to create a microgravity environment [130], [131]. 
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The HARV regulates horizontal rotation, laminar fluid flow, hydrodynamic forces, and 
oxygenation, making any manual work by the researcher minimal [130]. The cell line is 
simply entered into the culture chamber by syringe, and this chamber is placed on a rotator 
at 15 revolutions per minute in an incubator [132]. This vessel allows the cells to grow in 
suspension with minimal shearing, forming free-floating 3D tumor spheroids [131]. This 
method produces diverse results depending on the cell line used, and variations in size and 
morphology are a problem. 
Each of these four methods highlighted has limitations making them less effective for rapid 
preclinical drug development studies. Therefore, a better protocol would benefit the 
research community by facilitating the process to replicate in uniform size and in mass 
quantities. Herein, a novel method that can readily produce tumor spheroids with 
controllable size in large quantity and high uniformity is proposed. By using a special 
protein dispase, which only cleaves cell-Extracellular matrix (ECM) junctions, sparsely 
distributed tumor cell sheets are separated from the culturing surface.  By shaking these 
separated cell sheets within dispase-doped media, which prevents stacking of cell sheets, 
robust tumor spheroids are formed. The spheroids size can be controlled by tuning the cell 
sheet culturing period and spheroid shaking period. The uniformity can be controlled by a 
set of sieves which were custom-made by stainless steel meshes. Basic characterization 
was performed to study the viability, 3D structure and necrosis of the spheroids, and their 
application in drug screening is also demonstrated.  
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4.2 Experimental 
4.2.1 Materials and Cell Lines 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life Technology), 
supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% Antibiotic & 
Antimycotic (ThermoFisher). Fluorescence dyes (Calcein AM, and Propidium Iodide (PI)) 
were purchased from ThermoFisher. Dispase II was purchased from EMD Millipore.  
Doxorubicin and Paclitaxel were purchased from LC labs. p-nitrophenyl phosphate (PNPP), 
1-Step™ PNPP Substrate Solution was obtained from ThermoFisher.  All chemicals that 
are not mentioned are directly used without purifying.  
The human colorectal cancer cell line, HCT116, (purchased from ATCC) was used as 
model tumor cells in this work. Cultured in 5% CO2 and at 37 °C, HCT116 cells were 
incubated with DMEM. The medium was changed every 2 days. When the cells reached 
80-90% confluency, they were subcultured and 0.05% Trypsin - 0.53 mM EDTA was used 
for cell detachment. A431 (human epidermoid carcinoma cell line) and HeLa (human 
cervical carcinoma cell line), which were cultured under same conditions, were kindly 
provided by Dr. Damien Thevenin from the Department of Chemistry at Lehigh University. 
U87 MG cell line (human primary glioblastoma cell line) was purchased from ATCC. 
4.2.2 MCTS Formation and Size Uniformization 
At 70-90% confluency, the cells were trypsinized, centrifuged, and seeded at low 
concentrations (usually 800 cells per dish) in 6-cm tissue-culture treated dishes for a range 
of 5 to 14 days, to ensure a spare distribution. The cell density that was seeded onto petri 
dishes was less than 40/cm2. When a desired cell sheet size was reached the media was 
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aspirated, and after washing with PBS, the cells were treated with 500 L of dispase for 20 
minutes in the incubator. Medium was then added in addition to the dispase, at a 1:6 ratio 
of dispase to media. These dishes were then placed in the incubator on an orbital shaker at 
30 rpm. Usually spheroid formation could be observed after 72-hours and the media 
without dispase was changed every 48 hours using custom-made sieves (described in next 
section in detail) to refresh media as well as to remove dead cells and small debris. A full 
set of the sieves was used for spheroid size uniformization. Spheroids with a narrow 
distribution of size could be obtained using two sieves of adjacent sizes. Specifically as an 
example, spheroids which passed through the 500 µm sieve but did not pass through the 
400 µm sieve were considered to be spheroids of sizes from 400-500 µm. 
4.2.2.1 Custom-made spheroid size uniformization sieves 
The spheroid size uniformization sieves can be fabricated by centrifuge tubes and 
commercially available stainless steel meshes. As shown in Fig. 4.1-A, a 3D image shows 
the diagram of the sieves. The bottom tips of centrifuge tubes were removed by cutting. 
The centrifuge tubes were cut off close to the conical area. The stainless steel mesh was 
placed on a hot plate with a surface temperature slightly higher than the melting point of 
the centrifuge tube polymer (here we used polypropylene). The cut-off surface of the 
straight tube was gently pressed onto the mesh, until a slight melting happened to ensure a 
good seal. A layer of aluminum foil could help prevent bonding formation between the 
tube and hot plate, and when the polymer and mesh were cooled down, the aluminum foil 
could be easily peeled off. To attach the conical tube onto the mesh, both of them were 
heated close to an ethanol flame, and they were quickly pressed together with a good 
alignment. As long as the sealing was good and the polymers from both straight tube and 
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conical tube were bonded firmly, the sieves were compatible with autoclave and could be 
used for spheroid size uniformization. A set of sieves with different mesh sizes was 
fabricated, as shown in Fig. 4.1-B.  
 
Figure 4.1 Illustration (A) and the sample photos (B and C) of the autoclavable Sieves for 
Spheroid Size Uniformization. (D) Typical microscope image of a 149 µm stainless steel 
mesh, showing square holes with 149 µm side length. Spheroids that are filtered through 
this type of square mesh could be slightly larger than the mesh size, because they are soft 
and can squeeze to pass through the mesh. 
4.2.3 MCTS Characterization 
Basic phase contrast microscope images were obtained from Olympus IX70. Cell viability 
was measured via dead/live staining dye (Calcein AM to indicate the live cells, and PI to 
identify dead cells, diluted in PBS at 5 M and 10 M respectively) and observed by the 
same microscope. Spheroid histology was documented in spheroids of different size ranges 
following routine fixation, paraffin-embedding procedures, sectioning (5 µm), and H&E 
(hematoxylin/eosin) staining, which were performed by Histowiz (New York, USA).  
3D structure of tumor spheroids was obtained by optical coherence tomography (OCT), 
and see Ref. [133]–[135] for more information about this modality. Details of the 
configuration of the spectral domain OCT employed in 3D tumor spheroid imaging can be 
found in Ref. [136]. An individual tumor spheroid was placed in a petri-dish under the 
objective of the OCT system. A 3D dataset with 400 × 400 × 1024 pixels in each dimension 
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was obtained by OCT, which corresponded to an actual volume of 2.0 × 1.7 × 2.2 mm3 in 
XYZ directions. The total acquisition time for each dataset was ~10 s. A custom post-
processing procedure was employed on the obtained OCT dataset to retrieve 3D OCT 
structure images of the spheroid. Next, 3D rendering of the tumor spheroid can be 
generated from OCT structural images by Amira.  
Tumor spheroid vitality was characterized by a modified acid phosphatase (APH) assay, 
which was introduced in [137]. In brief, spheroids were placed into ultra-low attachment 
well-plate individually, and the well-plates were then centrifuged at 1500 rpm for 10 min 
using a NuAire CF 48-R centrifuge. The supernatant was removed carefully, and 200 L 
PBS was injected to wash away the remaining media. Centrifugation was repeated, and 
100 L PNPP was added, followed by a 90-min incubation at 37ºC. 10 L 2 N NaOH was 
used to stop the reaction and absorbance readings at 405 nm were recorded on a TECAN 
Infinite F200 well plate reader. 
4.2.4 Drug Test 
The therapeutic efficacy of Doxorubicin (Dox) and Paclitaxel (Pac) were evaluated in 3D 
spheroid-based assays. Uniformly sized spheroids of each cell line were chosen for 
treatment with a monolayer serving as control. Individual tumor spheroids (diameter ~ 400 
m) were transferred to round-bottomed 96 well plates, and incubated in drug-doped media 
for 72 hours with the following concentrations: 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 
nM, and 1000 nM in standard medium. Microscope images of the original tumor spheroids 
were captured, as well as images after drug treatment. The well-plates were then 
centrifuged at 1500 rpm for 10 min using a NuAire CF 48-R centrifuge. The supernatant 
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was removed carefully, and 200 L PBS was injected to wash away the remaining media. 
Centrifugation was repeated, and 100 L PNPP was added, followed by a 90-min 
incubation at 37ºC. 10 L 2 N NaOH was used to stop the reaction and absorbance readings 
at 405 nm were recorded on a TECAN Infinite F200 well plate reader. The data analysis 
was processed using OriginLab 8.5. 
4.3 Results and discussion 
4.3.1 Comparison between two types of typical 3D cell culture 
methods 
There are two main types of methods to form 3D tumor spheroids. (1) Seeding tumor cells 
into ultralow attachment rounded bottom wells and using gravity to let cells aggregated 
and form 3D spheroids, as shown in Fig. 4.2-B. The hanging droplet method shares the 
same idea. This method can be used for large spheroid formation, some of which can be as 
large as 500 μm, but the efficiency to form a large quantity of these spheroids is rather low, 
because only one spheroid can be formed in a well. (2) Give cells a scaffold. The scaffold 
could be hydrogel, mesh fibers, porous polymer or 3D printed hollow structure. Fig. 4.2-C 
shows a typical 3D tumor formation in a prevalently used hydrogel, Matrigel. This method 
can easily achieve a large quantity of spheroid demand, but the shape of spheroids cannot 
be controlled, as shown in Fig. 4.2-C. In most cases, the shape of spheroids is important 
because with regular shapes (usually spherical) the spheroids can be easily analyzed.  
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Figure 4.2 Comparison of HCT116 cells on 2D petri dish culturing (A), 3D spheroids 
culturing in ultralow attachment well plate (B), and 3D spheroids culturing in Matrigel (C). 
The three different cell culturing methods show a remarkable difference in cell behavior 
and cell morphology. 
4.3.2 Cellular Spheroids Formation Process using Dispase 
The cellular spheroids formation process can be illustrated as Fig. 4.3. Single cells are 
firstly seeded onto tissue-culture treated petri dishes. To ensure each cell have sufficient 
room to grow to be a separate cell sheet, the initial cell density/concentration should be 
low. After a few days of growth, cell sheets are formed. Dispase is a low toxicity protease 
[138] which only cleaves fibronectin, collagen IV and other cell-ECM connections, but 
barely affects cell junctions such as adherence junctions, so dispase treatment on tumor 
cell sheets are able to lift the intact sheets off petri dishes without breaking the sheets apart. 
What is more, dispase is not inhibited by serum, so it can work together with serum media. 
After lift-off, the cell sheets thicken in the vertical direction and shrink in the horizontal 
direction, due to the cells are released from the cell-dish tension and become much rounder 
other than flatter morphology on petri dishes. The lift-off cell sheets are then orbital-shaken 
with dispase doped media, and the edges began to curl, as shown in Fig. 4.3-D and Fig. 
4.4-B.  During the shaking process, dispase always acts as spheroid-spheroid connection 
inhibitor, and working together with the shear force, the spheroids can be always separated 
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without aggregation. The curling proceeded towards the center until it forms a closed shape 
in 24 h. Usually, after 72 h shaking in dispase doped media, a spherical shape can be formed. 
As significantly large size (usually average diameter >200 m) are formed, spheroids 
would expose to very large shear force, and so that it is impossible to form stable spheroid-
spheroid connection even without dispase. Therefore, dispase is not necessary in this case. 
Microscope images showing HCT116 tumor spheroids formation process can be found in 
Fig. 4.4 (A-E). 
 
Figure 4.3 Cartoon illustration of cellular spheroids formation. Single cells are seeded onto 
petri dishes (A), and after a few days of growth, cell sheets would form (B). Cell sheets 
can be detached off petri dishes by dispase and the sheets can be maintained (C). Shaking 
the cell sheets in dispase-doped media would let their edges folding (D) and eventually the 
cell sheets would become spheroids (E). 
 
Figure 4.4 Contrast microscope images of HCT116 tumor spheroids formation process. 
(A) HCT116 cell sheet (Sheet growth = 10 days) on petri dish and (B-E) cell sheet was 
detached by dispase and kept orbital-shaking at 30 rpm with dispase doped medium (1/6) 
for different time. All scale bars are 200 µm. 
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The speed of shaking was also identified to affect spheroid formation. Even though the 
cell-ECM and cell-petri-dish connections were inhibited by dispase, the cell-cell 
connection affinity was still retained. At a lower speed (30 rpm), aggregations began to 
form, but when the shaking speed was higher than 60 rpm, aggregation barely occurred 
and the spheroid growth showed little difference at different shaking speeds. However, 
since the circular petri dishes were under orbital shaking, secondary flow (Fig. 4.5) would 
induce spheroid collection in the center of petri dishes, especially when the shaking speed 
was higher and spheroids were bigger. This would cause insufficient nutrition and 
metabolite exchange and in some extreme cases that the spheroids would be continuously 
exposed to air. Therefore, a proper shaking speed is required to form and maintain robust 
spheroids.  
 
Figure 4.5 Secondary flow induced Spheroid collection at the center of the petri dish under 
orbital shaking. 
When the petri dish is under conditions of orbital shaking, it creates a primary spinning 
flow in the petri dish. A centripetal force toward the center is needed to maintain the 
spinning motion of the fluid. However, the fluid flow velocity near the boundary wall or at 
the bottom surface is much smaller than the spinning speed due to the wall friction and 
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viscous force in the boundary layers. To analyze the motion of the bulk fluid, e.g., not in 
the boundary layer, the forces between shear stress, gravity, pressure forces and momentum 
should be balanced. The shear stress is negligibly small compared with the pressure and 
inertial force. The gravity is perpendicular to the velocity, thus it can be safely ignored. 
The motion of the fluid element can be approximated by Euler’s equation,  
𝜕𝑃
𝜕𝑟
=
𝜌𝑉2
𝑟
 
However, for fluid flow close to the boundary layer, the velocity V is low, thus, the 
centrifugal acceleration cannot balance the pressure gradient. As a result, a secondary flow 
is formed with the fluid close to the bottom surface moving toward the center of the petri 
dish, as observed in the collection of spheroid in the center of the petri dish. This was 
explained by Albert Einstein [139]. 
Control experiments are performed. Shaking cell sheets in media without dispase would 
result in stacked cell sheets, as shown in Fig. 4.6-A; stopping shaking for 24 h would result 
in spheroids aggregation, as shown in Fig. 4.6-B; shaking single cell suspension other than 
cell sheets would also result in aggregations. Moreover, when the sheets culturing time was 
too long (more than 14 days), thick cell sheets would form, and shaking these cell sheets 
in dispase doped media would result in thick round shape cell flakes other than spheroids, 
as shown in Fig. 4.6-C. As shown in Fig. 4.6-A, when cell sheets are shaken in dispase free 
media, they tend to stack to each other, and form large aggregations. There are more and 
more evidence showing that tumor cells also produce ECM [140][141], and the possible 
reason for this phenomenon is cells on one sheet has a rather high affinity to ECM formed 
on another sheet in dispase free media, while in dispase doped media, the affinity is 
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inhibited, and cell sheets could curl separately and form spheroids. Dispase also softens 
cell sheets, making them much easier to curl.  Thick cell sheets which have multiple cell 
layers are not soft enough to allow curling happen, even though dispase is introduced, the 
cell junctions are still sufficiently strong to keep the sheet shape, so large and flat cookie-
like structure is formed, as shown in Fig. 4.6-C. On the other hand, stop-shaking allows 
cell junctions formation between spheroids, so they form large cell aggregates, as shown 
in Fig. 4.6-B, even though cell-ECM connections were inhibited by dispase. However, after 
significantly large spheroids were formed, the requirement for dispase to inhibited cell-
ECM connections became unnecessary, because the contact area between spheroids was 
much smaller than between cell sheets, leading to that spheroids had less possibility to bind 
to each other under similar sheer flow. This also explains spheroids directly formed from 
single cell suspension tend to form aggregation as well. Since dispase is expensive, and it 
has negligible negative effect on cell and spheroids growth, there is no need to keep dispase 
in media when significantly large spheroids were formed. Usually spheroids with diameter > 
200 μm are big enough to be shaking-cultured in dispase-free media. 
 
Figure 4.6 A few control experiments for tumor spheroids formation. (A) Controlled by 
using dispase-free media when shaking, the image was taken at shaking day 1; (B) 
Controlled by stopping shaking for 24h at day 7; and (C) Controlled by using large cell 
sheet (Sheet growth = 15 days), the image was taken at shaking day 5. All scale bars are 
200 µm. 
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4.3.3 Size Control 
A few factors will influence the size of spheroids: the time of cell sheet culturing, the time 
of spheroid shaking, the initial cell seeding density, and the nutrition supply. The spheroids 
size changes from different cell sheet growth time were recorded for up to 9 days, and the 
results were shown in Fig. 4.7-A. Obviously, the larger the original cell sheet, the bigger 
spheroid that would be obtained from the same cell sheet; and the longer the spheroids 
were cultured in shaken media, the bigger they would be. Larger spheroids tended to grow 
more slowly, as shown by the decreased slope in Day 7 and 9. The initial cell seeding 
density was another factor that influenced spheroids size. Spheroids size come from cell 
sheets grown for 7 days of four different initial cell seeding densities were recorded and 
results were shown in Fig. 4.7-B. Spheroids from higher cell density dishes were 
significantly smaller than the ones from lower cell density dishes. This could be explained 
by the nutrition supply was less in higher density dishes, since they had more cells and the 
media change was performed same as lower cell density dishes. Spheroids from the same 
filtered batch also showed size difference if they were split into dishes with different 
density. 
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Figure 4.7 Size control of HCT116 tumor spheroids. (A) Size comparison of spheroids 
from cell sheets cultured on petri dishes for different time (6 days to 13 days). Spheroid 
size was recorded on different shaking days (black, red, green and blue dots are recorded 
on shaking day 3, 5, 7, and 9, respectively). (B) Size comparison of spheroids from cell 
sheets that were from different initial cell seeding density. Spheroid size was recorded for 
12 days. Each data were obtained from at least 7 tumor spheroids. 
4.3.4 Cellular Spheroids Size Uniformization 
The size of spheroids produced by this method is not uniform (Fig. 4.8-A and H), because 
the original size of cell sheets are hard to control, and meanwhile cell clusters falling off 
from large spheroids could initiate new but smaller spheroids. To uniformize the spheroids, 
a set of autoclavable sieves are used (see the following part). Stainless steel meshes could 
be easily found from a lot of sources, and the mesh size could be varied in a rather wide 
range, so spheroids uniformly with different sizes can be obtained by using sieves made of 
these meshes. As shown in Fig. 4.8, the size distribution of HCT116 spheroids from the 
same batch as shown in Fig. 4.8-A in a full spectrum between 149 μm and 600 μm can be 
found. The diameter of filtered spheroids was slightly larger than the mesh size of the larger 
sieve used for filtration. For example, as shown in Fig. 4.8-E, spheroids filtered with 300-
400 m sieves in the same sample had a rather small variance in size between 370 and 570 
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m (Fig. 4.8-L). The reason leading to this would be spheroids are soft and flexible and 
they can squeeze through the meshes that are slightly smaller than themselves. What is 
more, the meshes are square shaped, which result in even smaller resistance for larger 
spheroids passing through. This also explains the relatively larger size distribution of 
spheroids than sizes of meshes that are used. The uniformity can be even improved by 
using less increment of stainless steel meshes. To obtain even more uniform spheroids, 
increments between adjacent sizes within 20-30 m can be found commercially, which 
would allow for the uniformity to be dramatically increased. For example, the upper image 
of Fig. 4.9 showed a low magnification image of highly packed spheroids filtered by 120 
and 144 µm sieves, with an equivalent diameter (range, mean±SD, CV, n) of (172-241 µm, 
201±13 µm, 6.35, and 460) respectively. The spheroids can be applied to 96-well or 384-
well straightforwardly for drug testing or other applications. Currently, we can only pipette 
each spheroid into the wells individually. 96 spheroids were randomly picked from the 460 
spheroids and placed into a 96 well plate. The bright field images of each spheroid in the 
well plate were shown in the lower figure of Fig. 4.9. 
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Figure 4.8 HCT116 tumor spheroids size uniformization. (A) A typical image showing the 
widely size-distributed tumor spheroids, taken at shaking day 7 (detached at sheet-growth 
day 9). (B-G) Tumor spheroids from the same batch as (A) filtered by different sieves. (H-
N) Tumor spheroids size distribution before and after filtration, vertically corresponding 
to (A-G). The numbers such as 149-177 in (I) mean such spheroids are filtered by using 
sieves with such size (µm) holes. Each spheroids count were counted and calculated from 
10-30 images taken at certain size distribution. All scale bars are 200 µm. 
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Figure 4.9 HCT116 spheroids from 120-144 μm sieves. (upper) Low magnification image 
of highly packed spheroids, and (lower) 96 randomly picked spheroids transferred to 96 
well-plate. Scale bar in the middle = 200 µm. 
75 
 
4.3.5 Toxicity of Dispase 
Dispase is a low toxicity protease [138] which only cleaves fibronectin, collagen IV, and 
other cell-ECM connections, while barely affecting cell-cell junctions such as adherence 
junctions. What is more, dispase is not inhibited by serum, so it can work together with 
serum media.  As such, dispase treatment on tumor cell sheets is capable of lifting intact 
sheets off of petri dishes without breaking the sheets apart. In our study, dispase was found 
to have negligible negative effects on cell and spheroid growth. HCT116 spheroids from 
the same batch were cultured under shaking-conditions in dispase-free and dispase-doped 
media, and the size change was monitored for 10 days. As the fluorescence images shown 
in Fig. 4.10- A and B, spheroids do not show a remarkable difference between shaking-
conditions in dispase-free and dispase-doped media in dead/Live staining, with most of the 
surface cells alive. The average size change over 10 days of culturing in the two situations 
also does not show a remarkable difference (Fig. 4.10-C), indicating a negligible negative 
effect of dispase on cell and spheroid growth. Additional evidence of live cell numbers in 
spheroids obtained from the two situations did not show remarkable difference (Fig. 4.10-
D). Dot plot results show that the cell to cell junction protein E-cadherin was not affected 
by continued dispase treatment (Fig. 4.10-E). Cell amounts were attempted to maintain 
consistent for the Dot plot. Same size and same amount of spheroids were used for the 
ultra-low attachment well plate spheroids (ULA 3D) culture and our method using dispase 
treatment (Dis 3D), and the amount of 2D cells was used based on the calibration curve in 
Fig. 4.14-B. As the results of Dot plot assay of E-cadherin in Fig. 4.10-E suggested, 2D 
cell culture showed rather dim signals for the four repetitive dots, while ULA 3D (spheroids 
formed using ultra-low attachment well plate) showed a strong signal, with similar intensity 
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as our method, which supported the hypothesis that dispase does not affect cell-cell 
junctions. 
 
Figure 4.10 Dead/Live staining fluorescence images for two typical HCT116 spheroids 
shaken with (A) and without (B) dispase. The size change of the two comparable spheroids 
was also recorded for 10 days, and the results are shown in (C), indicating that there was 
negligible difference between with and without dispase treatment. APH experiments (see 
next part) were also performed to prove the argument, and results are shown in (D). Only 
a single size of spheroid was studied (around 400 µm), and at least 12 spheroids were used 
for each point in (D). (E) Dot plot results show that the cell to cell junction protein E-
cadherin was not affected by continued dispase treatment. Scale bars = 200 µm. 
4.3.6 A few Characterizations of HCT116 Spheroids 
4.3.6.1 Viability investigated by Dead/Live staining 
Dead and live staining is used to examine the viability of HCT116 spheroids. As shown in 
Fig. 4.11, (A) shows a smaller spheroid with 325 μm diameter, and (B) shows a larger 
spheroid with 875 μm diameter. Live cells which emit green occupied almost all the surface 
of the two spheroids, with few dead cells which emit red. Confocal fluorescence 
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microscope is also used to examine deeper into the spheroids, but no desirable results are 
obtained possibly due to the low permeability of the dyes.  
 
Figure 4.11 Fluorescence microscope images of a typical small (A) and large (B) HCT116 
spheroids with Dead/Live staining. Scale bars = 200 m. 
4.3.6.2 Histology 
The inner structure is investigated by histology. As shown in Fig. 4.12-B, spheroids with a 
smaller diameter (~258 µm) did not exhibit central secondary necrosis, while the larger 
ones (~580 µm) developed central cell death and formed necrosis. The thickness of viable 
cell shell for the spheroids is about 200 µm, which supports the conclusions made by plenty 
of publications that the maximum thickness of viable cell shell for spheroids is about 150-
200 µm [142].  
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Figure 4.12 Histology of HCT116 tumor spheroids. (A) A relatively smaller spheroid with 
about 250 μm diameter, and (B) a relatively larger spheroid with about 520 μm diameter. 
4.3.6.3 OCT 
The 3D structure information was examined by OCT. As shown in Fig. 4.13, spheroids 
with both smaller and larger diameters could retain a spherical shape. Optical coherence 
tomography (OCT) [143]–[145] is a three-dimensional (3D) biomedical imaging modality 
based on low-coherence interferometry. OCT detects back-scattered light and reconstructs 
a 3D image of microstructures within the tissue, with a field of view close to a standard 
bright field microscope and light penetration of up to 1-2 mm below the tissue surface. 
OCT scanning is fast, non-invasive and label-free. Moreover, obtained OCT images have 
micron-scale resolution in both axial and transverse dimensions [146]. OCT has its wide 
applications in the field of ophthalmology and cardiology [147], [148]. Recently, several 
groups have employed OCT to quantitatively characterize the 3D tumor spheroids [149], 
[150]. 
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Figure 4.13 Two-dimensional (2D) phase contrast microscopic image of a large tumor 
spheroid with a measured diameter of 1205 µm. B. 2D cross-sectional image of the tumor 
spheroid obtained by optical coherence tomography (OCT). OCT is able to detect back-
scattered light within the tumor spheroid from depths close to 1 mm below the top surface 
of the spheroid. C. 2D top view image of the tumor spheroid by OCT. D. 3D rendering of 
the tumor spheroid by OCT to characterize the overall shape and size of the tumor spheroid. 
E. 2D bright field image of a small tumor spheroid with a measured diameter of 558 µm. 
F. 2D cross-sectional image of the small tumor spheroid by OCT. G. 2D top view image 
of the small tumor spheroid by OCT. H. 3D rendering of the small tumor spheroid by OCT. 
With this culture method, tumor spheroids can retain a spherical shape for a long time with 
their diameters growing over 1 mm.    
4.6.4 Relationship between live cells amount and spheroid size 
Viable cell numbers per spheroid was another important parameter of tumor spheroids, 
which was a prerequisite for the evaluation of commercial cell viability/cytotoxicity assays. 
The acid phosphatase (APH) assay, which is based on quantification of cytosolic acid 
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phosphatase activity, was validated for determining cell viability in spheroids [137]. APH 
assay was performed on different sizes of spheroids, and interestingly a linear relationship 
was found between the spheroids diameter and viable cells numbers in the spheroids, which 
accorded with the findings in the literature [137]. The linear calibration of viable cell 
numbers to the absorbance at 405 nm in well plate can be found in Fig. 4.14. 
 
Figure 4.14 The relationship between live cell number of single cell suspension in a well 
of 96 well-plate and its absorbance at 405 nm on a well-plate reader (A), and the 
relationship between live cell number of spheroids with different sizes and live cell 
numbers (B). Both showed a linear relationship. (B) was plotted with about 130 spheroids 
with size ranging from 300 µm to 1200 µm.   
4.3.7 Tumor Spheroids used in Drug Screening 
To examine the drug-screening applications of this invention, Paclitaxel and Doxorubicin 
are used to test the drug-resistance of tumor spheroids and a comparison to monolayer cell 
culture is made. Both the two drugs show excellent cytotoxicity to HCT116 cells [151], 
[152], even though the mechanisms are different. Robust single HCT116 spheroids with 
about 500 µm in diameter obtained by 446-470 µm sieves, are seeded per well of 96 well 
plate. Paclitaxel and Doxorubicin in different concentrations doped media are treated the 
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spheroids for 72 h. As shown in Fig. 4.15, after 72 h treatment, the 300 nM Paclitaxel 
treated spheroid is broken and obviously the volume is not as large as the control, showing 
a remarkable cell loss. APH assay is used to determine the drug effect of the two drugs on 
the tumor spheroids. As shown in Fig. 4.16, tumor spheroids show a remarkably higher 
drug-resistance than monolayer cell culture. By comparing the two drugs, paclitaxel shows 
less difference between tumor spheroids and monolayer cell culture. For example, APH 
activity in monolayer was reduced about 70% with 72 h of 50 nM Paclitaxel treatment, 
compared to about 35% in spheroids, while with the same time and same concentration of 
Doxorubicin treatment, APH activity in monolayer was reduced about 95%, compared to 
just about 20% in spheroids. This indicated that HCT116 spheroids had higher drug-
resistance to Doxorubicin than monolayer cell culture, compared to Paclitaxel. The half 
maximal inhibitory concentration (IC50) or half lethal concentration (LC50) values in 
spheroids culture were 124 ± 20 nM for Doxorubicin and 110 ± 19 nM for Paclitaxel, and 
IC50 values in monolayer cultures were 9.22 ± 4.25 nM for Doxorubicin and 26.3 ± 12.5 
nM for Paclitaxel. A set of 3D rendered OCT images of drug-treated spheroids were shown 
in Fig. 4.17. The initial size of spheroids were about 250 µm. The spheroid which did not 
receive any drug treatment showed an intact spherical shape and grew to about 420 µm 
diameter in 72 h, while the spheroid treated with 500 nM Paclitaxel was broken, with dead 
cells burst out of the spheroid. Although no such dead cell burst was found in Fig. 4.17-C, 
which was a spheroid treated with 500 nM Doxorubicin for 72 h, the integrity of the 
spheroid was not as intact as the untreated one, and the volume was obviously smaller than 
the spheroid in Fig. 4.17-A. Actually, since the handling was careful, the two drug-treated 
spheroids did not experience severe shaking and high shear rate. One time of media change 
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or pipetting would break the drug-treated spheroids, which was another proof that the 
structure of such spheroids was rather loose. On the contrary, the untreated spheroid would 
stay intact no matter how many times of handling and transfer occur. Here, we mainly 
demonstrate the tumor spheroid formation method, and the mechanism of the difference 
between drugs still needs further studies.  
 
Figure 4.15 Spheroid integrity after treatment with Paclitaxel and Doxorubicin. 
Representative phase contrast images of the original spheroids (A), controlled spheroids 
after 72 h non-drug treatment (B), spheroids with 10 nM (C) and 500 nM (D) Paclitaxel 
for 72 h, and spheroids with 10 nM (E) and 500 nM (F) Doxorubicin for 72 h. Similar size 
spheroids (diameter ~500 µm) were treated with different concentrations of Paclitaxel and 
Doxorubicin for 72 h, and (A) shows a typical controlled spheroid, while (B) shows a 
spheroid that was treated by 300 nM Paclitaxel for 72 h. All scale bars are 200 µm. 
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Figure 4.16 The drug effect on HCT116 tumor spheroids by APH assay. Drug effects of 
Paclitaxel (A) and Doxorubicin (B) in spheroids cultures, with comparison to monolayer 
cell cultures. Dose-response curves were plotted exponentially. 
 
Figure 4.17 3D rendered OCT images of spheroids after drug treatment for 72 h: (A) 
Control, (B) Paclitaxel (500 nM), and (C) Doxorubicin (500 nM). The initial size of 
spheroids was about 250 µm. 
4.3.8 Other cell lines 
Other than HCT116, this method has been successfully used for HeLa (human cervical 
carcinoma cell line), A431 (human epidermoid carcinoma cell line) and U87 MG (human 
primary glioblastoma cell line) tumor spheroids formation, as shown in Fig. 4.18. HeLa 
cells grow much slower than HCT116 and A431, but after relatively longer time of 
culturing, spheroids with desired sizes can still be obtained. Although currently this method 
is still only used on tumor cell lines, we believe it can be used on primary cells. 
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Figure 4.18 Other cell lines can also form high quality and high uniformity robust 
spheroids by using this method. (A) Typical microscope image of HeLa tumor spheroids 
shaken for 14 days from cell sheet culturing for 7 days; (B) Typical microscope image of 
A431 tumor spheroids shaken for 4 days from cell sheet culturing for 7 days; and (C) 
Typical microscope image of U87 MG tumor spheroids shaken for 9 days from cell sheet 
culturing for 9 days. Scale bars = 200 µm. 
4.3.9 Advantages and improvements over existing methods, 
devices or materials 
Table 4.1 shows the advantages and disadvantages of our method and other popular 
methods on tumor spheroid formation. Depending on the initial cell seeding concentration 
and culturing time, both Liquid-Overlay and Hanging-Drop methods showed advantages 
on uniformity and size controllability. However, each spheroid formed in a droplet or in a 
well, which lead to low efficiency on quantity, showing a remarkable drawback on 
applications that needed large amount of spheroids, such as drug screening. These two 
methods also do not allow for dead cell removal, which might have negative interference 
on some applications. The spheroid growth is even more restricted in the Hanging-Drop 
method, due to it being nearly impossible to change media. There are commercially 
available devices that can be used for tumor spheroids formation based on the principle of 
Liquid-Overlay and Hanging-Drop methods, such as the Corning® Costar® Ultra-Low 
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Attachment 96 Well Plate and the Kuraray® ‘Multiple Pore Type’ device. The basic 
principle of the Corning ultra-low attachment well plate is the same as the Liquid Overlay 
method, and it is one of the most standard methods for tumor spheroids generation 
nowadays. The Liquid Overlay method was performed in the well plate and the equivalent 
diameter (range, mean ± SD, CV, n) of the obtained spheroids are (275-350 µm, 312 ± 23 
µm, 7.37, 32), respectively, which was similar to our results. However, our method still 
shows remarkable advantages such as high quantity, media refresh, dead cells removal, and 
cost reduction over Liquid Overlay method. The basic principle of the ‘Multiple Pore Type’ 
device by Kuraray is similar to the Hanging Drop method, but this device shows higher 
productivity and convenience. However, since the initial seeding is introduced at once to 
the whole chamber of the device, the number of cells that fall into each hole would vary, 
leading to a large variance in the formed spheroids size. As the results show on the Kuraray 
website, the size of spheroids formed with the devices was more widely dispersed 
compared to our method (Fig. 4.9). 
It is easy to produce large amount of spheroids using the Magnetic levitation and NASA 
Bioreactor methods, and media exchange is much easier to realize, however the uniformity 
and size controllability are not attainable. Our method, on the other hand, basically 
gathered most of the advantages and avoided most of the disadvantages mentioned: the 
average size of spheroids can be controlled by tuning the cell sheets culturing period and 
spheroid shaking period; the uniformity can be controlled by a set of sieves which were 
custom-made by stainless steel meshes; thousands of spheroids can be produced from 
rather limited initial cell populations within 2 weeks without expensive consumables and 
sophisticated instruments and skills; frequent media exchange ensures robust spheroid 
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growth; and dead cells and debris can be easily removed. For cost-effectiveness, as an 
example, our method also shows an extreme advantage over the Liquid-overlay method. If 
only considering the extra costs for making these spheroids (costs beyond tissue culture), 
our method only needs dispase solution and after calculation the maximum cost for a single 
spheroid is only $0.00275. In contrary, the Liquid-overlay method needs $0.149 for a 
spheroid in a well (Corning® Costar® Ultra-Low Attachment 96 Well Plate). In the 
calculation, the 800 cell/dish original seeding density was assumed to yield 200 desired 
size spheroids (which is a minimum estimation, because usually much more spheroids with 
desired size can be obtained), and only 1 mL dispase solution was needed. In fact, for 
smaller spheroids, 2000 cell/dish seeding density was also tried and can easily result 
in >1000 spheroids of desired size. A few quantitative comparisons were made in Table 
4.2, in which most data were from [153]. Our method showed obvious advantages over 
other methods. It may find applications in anti-cancer drug screening, in vitro tumor studies, 
and may also be applied to primary cellular spheroid formation or even multi-cell type 
spheroids and organoid formation. 
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Table 4.1 Advantages and disadvantages of our tumor spheroid formation method and 
other popular methods. 
  Advantages Disadvantages 
Liquid-Overlay [124] 
Uniformity 
Controllable size 
Media refresh 
Low quantity 
No dead cells removal 
Hanging-Drop [120] 
Uniformity 
Controllable Size 
Low quantity 
No media refresh 
No dead cells removal 
Magnetic Levitation 
[127] 
High quantity 
Media refresh 
Low uniformity 
Uncontrollable size 
Introduce magnetic particles 
NASA Bioreactor [130] 
High quantity 
Media refresh 
Bioreactor needed 
Low uniformity 
No dead cells removal 
This method 
High quantity 
High uniformity 
Controllable Size 
Media refresh 
Dead cells removal 
Facile 
Inexpensive 
Relative long time on cell 
sheet growth 
Manual steps on size 
uniformization  
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Table 4.2 Quantitative comparison between our method and other methods. The data of 
the three methods except Liquid Overlay were from [153]. 
  
*Time 
Require
d (day) 
*No. 
Cell 
Require
d (×106) 
Equivalent 
Diameter (µm) 
(range, 
mean±SD, CV, 
n) 
Amount of 
Harvested 
Spheroids  
▼Ratio of 
Spherical 
Spheroids 
(SI ≥ 0.9) 
&Liquid 
Overlay 
7 3 
275-350, 
312±23, 7.37, 32 
A well a spheroid High 
Hanging-
Drop  
7 0.6 
200–500, 
359±95, 26.5, 38 
A drop a 
spheroid 
Low 
Magnetic 
Levitation  
7 0.5 
200–500, 
347±87, 25.1, 28 
No Limit Low 
NASA 
Bioreactor  
15 40 
500–1100, 
897±98, 11.0, 
192 
No Limit Low 
This 
method 
#9-15 
0.0001-
0.001 
▲172-241, 
201±13, 6.35, 
460 
No Limit Very High 
*Time and number of cells needed to obtain sufficient spheroids to fill a 96-well plate; 
&Liquid Overlay was performed by using the Corning® Costar® Ultra-Low Attachment 
Multiple Well Plate, and the initial seeding density was 3000/well. A centrifuge was 
performed after cell seeding to ensure a high level of sphericity. Without centrifuge, 
spheroids would have low ratio of SI ≥ 0.9. 
#Depending on which size spheroid was needed, bigger ones needed more time; 
▲The data was obtained from 460 spheroids filtered by 120 and 144 µm sieves; 
▼Referring to [154], the SI = Sphericity index was calculated from 𝑆𝐼 =
π√
4A
π
P
 , where A 
and P was the projected area and perimeter of spheroids obtained from ImageJ; the case 
that > 90% spheroids were spherical (SI ≥ 0.9)  was considered ‘very high’, > 50% was 
considered ‘high’, and < 50% was considered ‘low’. 
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4.4 Conclusions 
A facile method for generation of tumor spheroids in large quantity with controllable size 
and high uniformity was presented. Dispase was used to detach cell sheets that were 
cultured from sparsely distributed cells for several days, and the cell sheets shape was 
maintained. These detached cell sheets were transferred to dispase-doped media under 
orbital shaking conditions. Assisted by the shear flow under shaking and inhibition of cell-
to-extracellular matrix junctions by dispase, the cell sheets curl up and eventually tumor 
spheroids were formed. The average size of the spheroids could be controlled by tuning 
the cell sheet culturing period and spheroid shaking period. The uniformity could be 
controlled by a set of sieves which were custom-made using stainless steel meshes. Since 
this method is based on simple petri-dish cell culturing and shaking, it is rather facile for 
forming tumor spheroids with no theoretical quantity limit. This method has been used to 
form HeLa, A431 and U87 MG tumor spheroids and application of the formed tumor 
spheroids in drug screening was also demonstrated. The viability, 3D structure, and 
necrosis of the spheroids were characterized. The method can be applied in anti-cancer 
drug screening, in vitro tumor studies, and may be applied to primary cellular spheroid 
formation or even multi-cell type spheroid and organoid formation. 
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Chapter 5:  Bi-layer blood vessel 
mimicking microfluidic platform for 
tumor drug screening based on co-
culturing 3D tumor spheroids and 
endothelial layers 
5.1 Introduction 
Traditional tumor drug screenings utilize 2D cell monolayers. Although it is an easy-to-
handle model suitable for automation and is favorably used in High Throughput Screening 
(HTS) systems [155]–[157], using 2D tumor cell monolayers for drug screening purposes 
is not a realistic recreation of tumors in an in vivo environment. This is because 2D cell 
culture does not mimic the essential cell-cell or cell-ECM interactions present in vivo, 
which presents a crucial limitation for accurately estimating the efficacy of a tumor drug 
in the human body. There is overwhelming evidence that in vitro 3D tumor cell cultures 
more accurately reflect the complex in vivo microenvironment than simple 2D cell 
monolayers, with respect to gene expression profiles, signaling pathway activity and drug 
sensitivity [158]–[163]. For example, some tumor cell lines developed dense multicellular 
spheroids in 3D-culture, and showed greater resistance to Paclitaxel and Doxorubicin as 
compared to the 2D-cultured cells [164]–[169][170]. Therefore, utilization of 3D tumor 
models increases the accuracy of tumor drug screening results. 
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Most of the 3D cellular models are focused on 3D spheroids, due to the ease of formation 
and enhanced manipulation [171]–[175]. Of the 3D spheroid models, tumor spheroids 
models are the most successful and widely-applied research tools for cancer studies and 
drug screening [171], [174]–[178]. Studies have been performed to make the morphology 
and physiology of the tumor spheroid similar to those in vivo, i.e. the network of cell-cell 
interactions, the three-dimensional structure, the presence of a natural extracellular matrix 
and nutrients, metabolites and oxygen gradients [179]. More evidence has been found that 
the tissue structure determines the growth rate of a tumor as well as its response to 
anticancer drugs [180]. Despite a variety of advantages offered by 3D tumor spheroids for 
drug screening applications as described above, they are infrequently utilized for drug 
screening. Limitations include a low number of effective spheroid cultivation methods, 
difficult quantitative determination of cellular responses in the 3D arrangement, and little 
drug transportation information, etc. Microfluidic devices, which emerged recently, are 
believed to be a good solution to these limitations [181]. Microfluidic devices can be 
fabricated to have multiple regions to facilitate increased spheroid formation and allow 
nutrition or cell gradients to dictate the size of the spheroids produced. Additionally, drugs 
can be introduced in a gradient manner, which dramatically increases the device efficiency 
[182]. The implementation of microfluidic systems into 3D tumor cell culture can 
compensate for the absence of vasculature, support nutrition supply, and allow for fluid 
dynamic studies. 
Although plenty of work has been focused on microfluidic-based 3D tumor spheroids drug 
screening [181]–[184], there is no pilot study which pays attention to the transportation of 
the drug through blood vessels and its negative effects on drug efficacy. Our group has a 
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series of well-defined studies on blood vessels in vitro which allow for mimicked drug or 
nano-drug transportation in the blood vessel environment, based on bi-layer microfluidic 
device [185]–[187]. This shows that the endothelial cell monolayer is an obstacle for drug 
transportation, and it is possible to manipulate the permeability of the endothelial cell 
monolayer by adding specific chemicals such as thrombin. 
Thus, in this work, a bi-layer microfluidic device for in vitro blood vessel mimicking and 
tumor drug screening was proposed. The bi-layer microfluidic device consists of two 
PDMS pieces with channels, and the two pieces are separated by a semi-permeable 
membrane which allows water, oxygen and nutrition supply to pass through, but prevents 
cell migration. The two channels on the two PDMS pieces have long sections of channel 
which overlap to ensure a larger exchange area to mimic the blood vessel-tumor model. 
High concentrations of EC are first seeded onto the membrane through the apical channel, 
and after a two-day culture to ensure the formation of a confluent EC monolayer, tumor 
spheroid laden Matrigel was seeded into the basal channel. After the Matrigel was cured in 
an incubator for 30 min, the devices were ready for drug testing. Confocal imaging and 
ImageJ were used to assess the efficacy of different drug concentrations and combinations 
of drugs therapies. Optical coherence tomography was employed to determine the tumor 
shrinkage after drug treatment. 
5.2 Materials and methods 
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5.2.1 Materials 
The media used for the HCT116 cells was Dulbecco’s Modified Eagle’s Medium (DMEM, 
Life Technology), supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% 
Antibiotic & Antimycotic (ThermoFisher). Fluorescence dyes (Calcein AM, and 
Propidium Iodide (PI)) were purchased from ThermoFisher. Dispase II was purchased from 
EMD Millipore. Paclitaxel was purchased from LC labs. PDMS is Sylgard 184 from Dow 
Corning. All chemicals that are not mentioned are directly used without purifying. 
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Figure 5.1 Diagram of microfluidic devices using PDMS molds with basal and apical 
channels. The basal channel is the straight channel on the bottom layer of the device, where 
cells like human colon cancer cells (HCT116) can be grown. The next layer is the semi-
permeable membrane and the top layer is the apical channel, which is the Z-shaped channel. 
Media is added to the apical channel and nutrients go through the membrane to the cells in 
the basal channel. Waste can be transported back through the membrane to the apical 
channel and removed from the apical channel outlet. 
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5.2.2 Drug 
Paclitaxel is a microtubule-active drug that inhibits mitotic progression and arrests cells in 
mitosis[188], [189]. Following mitosis arrest, cells may either exit from mitosis or undergo 
apoptosis. Evidence was found that low concentrations of paclitaxel induce cell-type-
dependent p53, p21, and G1/G2 arrest. However, for HCT116 and other cell lines, 
Paclitaxel cannot readily induce p53, and therefore these cells can undergo exclusively 
mitotic and postmitotic arrest after Paclitaxel treatment [190].  
5.2.3 Design of microfluidic devices 
To ensure sufficient nutrition and oxygen supply and better metabolite clearance, the 
microfluidic devices were designed as shown in Fig. 5.1. Both apical and basal pieces were 
made with PDMS, and the channels in them were replicated from a pre-obtained silicon 
wafer by photolithography. The two pieces were separated by a semi-permeable membrane, 
which usually has dense 200-800 nm pores, allowing water, nutrition, oxygen, and 
metabolites diffusion, while preventing cells transportation. Four outlets on the apical piece 
were matched to the four circle areas for the apical and basal channels. The two channels 
share the same size (500 µm width and 200 µm height) and they have more than 80% 
overlapping area, as shown in Fig. 5.1. Since the two PDMS pieces were separated by the 
semi-permeable polyurethane membrane, which has a surface that cannot be activated by 
plasma treating, an additional thin layer of PDMS was applied onto the whole membrane, 
excluding the channel area to ensure strong bonding. 
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5.2.4 Fabrication of the microfluidic devices 
PDMS (Sylgard 184) was obtained by mixing a base agent and curing agent at a ratio of 
10:1 (v:v), respectively. PDMS was poured onto the prepared molds, and bubbles were 
removed via vacuum for 30 min. Molds were cured in a 60oC oven for 30 minutes. PDMS 
with imprinted channels were peeled carefully from the mold, and cut into rectangular 
pieces. Basal channels were on the top and bottom of the straight channel while the apical 
channels formed the Z-shape. A piece with only the basal channels was paired with one 
piece with only apical channels; these were then aligned to have symmetrical outlets and 
to match well overall. The centers of the basal outlets were matched on the apical piece, 
and the apical piece was then removed. A biopsy punch was used to cut four holes for the 
four outlets on the apical piece; this includes two holes for the apical channel and two for 
the basal channel. In order to ensure smooth and efficient cutting, the channels were 
punched powerfully and quickly. Subsequently, the basal piece and a glass slide were 
cleaned using acetone and after drying, the surfaces were activated by an oxygen plasma 
handgun treatment for at least 30 s. The basal piece and glass slide were then attached, and 
any bubbles were removed. The channel side of the basal piece was then cleaned with 
acetone and plasma treated again, and the smooth side of a semi-permeable membrane was 
attached to the channel side of the basal piece. A thin layer of PDMS was then applied onto 
the film without touching the channel area. Being careful that PDMS was not applied to 
the channel was important because the PDMS should not spread to and permeate the 
channel. The PDMS-coated pieces were then cured on a hot plate for 15 min. The film 
covering the two outlets on the basal pieces were then cut and removed to expose the outlets. 
The apical piece of the channel was then cleaned with acetone, and the PDMS-coated 
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surface and apical piece were then plasma treated. Since the attachment process is 
irreversible, the apical piece was attached onto the film by matching the channels, holes 
and outlets slowly and carefully. The piece was then cured in a 60°C oven for 30 min. The 
devices were autoclaved at 100°C for 20 min for sterilization purposes, and dried for 5 min. 
5.2.5 Endothelial layer seeding (seed EC first) 
Bovine aortic endothelial cells (BAEC, we use EC for short) were used as the endothelium 
model. Since ECs need some cell adhesion motifs to help them attach and grow, both apical 
and basal channels were incubated in an incubator with 0.2% porcine gelatin solution 
overnight (or for at least 3 h). EC from a confluent petri dish were harvested to obtain a 
1×107 cells/mL concentration. A droplet of EC suspension was applied to an outlet of the 
apical channel and was sucked through the channel by negative pressure using a disposable 
pipette. After 3 h of incubation, which allowed the ECs to attach to the bottom (the semi-
permeable membrane) of the apical channel, EC media was introduced to sustain nutrition 
supply. A confluent monolayer of EC formed in two days. The devices were placed in a 
large cell culture dish with drops of sterilized water placed around it to make the 
environment more humidified in order to prevent the devices from drying. 
5.2.6 Tumor spheroid formation, harvest, filtering and seeding 
The tumor spheroids were formed and filtered to uniform sizes as described in Chapter 4. 
In brief, a low concentration of HCT116 cells was seeded into 6-cm diameter petri dishes, 
and after 5-7 days of growth, dispase was used to detach the cell sheets, which were then 
orbitally-shaken in dispase-doped media in the same petri dishes for at least 3 days. A set 
of custom filters were used for size uniformization. In this work, the HCT116 tumor 
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spheroids were from 100-120 µm sieves, which means the spheroids which passed through 
the 100 µm sieve but did not pass through the 120 µm sieve were used in the study. The 
average size of the spheroids was 151 ± 24 µm. To create the tumor spheroid seeding 
mixture, the tumor spheroid suspension was diluted with Matrigel at a volume ratio of 1:1. 
The tumor spheroids were then seeded in the microfluidic device by placing the obtained 
mixture into an outlet of the basal channel and sucking on the opposite outlet of the channel 
with a disposable bulb pipette. This allowed for the cell suspension to flow throughout the 
whole basal channel. The device was placed in the 37 °C incubator for 30 min to cure the 
Matrigel. To apply the media, the disposable bulb pipette method was used to administer 
media to the apical channel. Since two cell types were involved, the EC media was used. 
HCT116 can be sustained in EC media, with no remarkable negative effects observed in 
using EC media to culture HCT116. 
 
Figure 5.2 Longitudinal cross-section diagram of the bi-layer blood vessel mimicking 
microfluidic device. 
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5.2.7 Drug Testing 
Paclitaxel was used as a model drug for the HCT116 spheroids treatment. The drug displays 
a remarkable efficacy on HCT116 [188], [189], but also on endothelial cells [191], [192]. 
Thus, the endothelial layer in the device not only mimicked the blood vessel and its 
permeability, but also could serve as the indicator for the toxicity of drug therapy on healthy 
cells. The drug was dissolved in EC media and diluted to different concentrations (0 M 
(control), 1nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM and 1 µM), and the drug was applied 
using a syringe pump for a series of time range (a few hours to a few days). To demonstrate 
the advantages of our platform, comparison of spheroids in a well plate, an EC-free device, 
and an EC device were made. To achieve the best drug efficacy—greater tumor cell death 
and less EC death—comparison of viability between EC and tumor cells was also made. 
5.2.8 Characterization 
There are two main principles to assess the efficacy of a drug or therapy for tumor treatment. 
One is to measure the population of dead and live cells in a 3D tumor spheroid, which can 
be achieved via dead/live staining and confocal microscopy. The second way is to observe 
the shrinkage ratio (or volume change) of the 3D tumor spheroid, which can be achieved 
using Optical Coherence Tomography (OCT). 
5.2.8.1 Dead/Live Staining 
The control and drug-treated 3D tumors were stained with a Calcein AM and propidium 
iodide (PI) (Dead/Live) staining kit. To ensure a better staining effect, double the 
recommended concentrations of the dyes and longer staining time (2h) were used. After 
staining, PBS flow was introduced for at least 1h to clear any unbound dye. 
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Confocal fluorescence microscopy was used to quantify the efficiency of the drugs by 
comparing the dead and live cells in a certain plane of the spheroids. Since usually the 
spheroids size is larger than 200 μm, only the 4X objective lens can cover this large area, 
but lacks good z-resolution. Thus, the stacks obtained in the middle of spheroids are usually 
blurred and mixed with the signal from different layers, which were not easy to enumerate. 
In contrast, the confocal images taken from the surface of spheroids were more vivid. By 
comparing the different z-stacking images, we found that the live and dead cell ratio on the 
spheroid surface could accurately represent the live-dead cell ratio of the whole spheroid. 
Since the cells were highly compact in confocal images, ImageJ (FIJI) was used to process 
the images and enumerate the dead and live cells, as shown in Fig. 5.3.  In brief, an image 
that could represent the surface of the spheroid was selected and transferred to a 16-bit 
gray-scale image. The threshold was then tuned to ensure that most of the out-of-focus 
cells were removed. Usually there would be some leftover cells that are packed together, 
and these could be distinguished by a plugin algorithm called Watershed, which can build 
dams to separate packed cells. Followed by Watershed, the Analyze Particles function was 
run to enumerate the total in-focus cells. The pixel cut-off was selected as larger than 50 
pixels, which correlates to half the size of a cell with 10 μm diameter. Both live and dead 
cells can be counted in this way. 
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Figure 5.3 Diagram of how to use FIJI to enumerate cells in highly packed condition. 
(A)(B), transfer color images to 16-bit gray-scale images. (B)(C), tune threshold to 
remove most of out-of-focus cells and keep most of the in-focus cells. (C)(D), run 
Watershed in FIJI to distinguish the highly packed cells. Run Analyze Particles function to 
count the cells in image D.  
Based on the enumeration of dead and live cells, the relative viability and drug efficacy 
were defined as 
Relative viability =
Number of live cells at certain drug concentration
Number of live cells at control condition
                Eq. 4-1 
Drug Efficacy = 1- Relative viability 
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5.2.8.2 OCT for determination of 3D tumor shrinkage  
OCT is an optical technique based on low-coherence interferometry, which is capable of 
obtaining 3D images. This technique does not require any staining and uses near-infrared 
light which allows for deeper penetration into tissue samples during scanning in a non-
invasive manner. It can also provide information about the volume of scanned objects. 
Because the surroundings of the tumor spheroids are transparent in this 3D tumor model, 
it is ideal to use OCT to monitor the size or volume changes of the 3D tumor spheroids. 
The volumetric quantification of 3D tumor spheroids was performed by a voxel-based 
method, which was described in detail in [136]. First, a 3D average filter was applied to 
remove the speckles within tumor spheroids in the OCT images. Then, the tumor spheroid 
was segmented using a canny edge detection filter, frame by frame. Connective voxels 
were grouped and the mean distance of grouped connective voxels to the manually chosen 
spheroid centroid was calculated. The group with the minimum mean distance was 
identified as the spheroid region. The voxels within this region were summed and then 
multiplied by the actual volume of an individual voxel (volume/voxel), yielding the total 
volume of the spheroid. 
The volume change of the spheroids at different drug concentrations was defined as 
Volume change =
Volume at certain drug concentration
Volume at day 0
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5.3 Results and Discussion 
5.3.1 Dead and live staining 
 
Figure 5.4 Confocal and bright field images of a HCT116 spheroids in the bi-layer device. 
(A) Calcein AM stained, (B) PI stained, (C) stack of (A) and (B), and (D) bright field image. 
The viability and drug efficacy of both cell types can be assessed using dead and live 
staining and confocal microscopy. It is relatively easier to address such parameters for EC. 
But for HCT116 spheroids, which are in a 3D conformation, and the size of which are 
usually larger than 200 µm, a 4X objective lens had to be used to image them, leading to a 
low resolution in the z direction. It is therefore difficult to obtain an overall viability using 
confocal 3D scanning. However, since cells on the spheroid surface can be clearly imaged, 
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as shown in Fig. 5.4-A, the viability of the spheroid surface was used to represent that of 
the whole 3D spheroid. As shown in Fig. 5.4, a freshly prepared HCT116 spheroid of 
approximately 150-μm diameter was stained with dead/live staining, and showed a strong 
robustness on the surface close to the objective of the microscope, with only one red spot 
which represents a dead cell. The spheroid was obtained using a set of 105-μm and 114-
μm filters, and this spheroid size was chosen for all of the following studies. This 
intermediate size allowed for the spheroids to be accessibly seeded into the devices as well 
as never exceeding the imaging limit of our microscope as the spheroids grew in size. 
5.3.2 OCT scanning and volume information  
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Figure 5.5 OCT scanning images of HCT116 spheroids in the device. (A) Cross-section 
of a HCT116 spheroid perpendicular to the channels, (B) cross-section of the spheroid 
parallel to the membrane, and (C) a 3D rendered OCT image of the spheroid. (A) and (B) 
share the same scale bar in (B). 
As mentioned in the previous chapter, OCT is one of best ways to obtain 3D information 
of biological samples in the range of sub-mm to 10-mm. As OCT utilizes the refractive 
index of transparent objects to reproduce 3D images, all the OCT scanning was performed 
through the glass bottom of the devices to avoid interference from the translucent semi-
permeable membrane. As shown in Fig. 5.5, A shows an image of a cross-section 
perpendicular to the channel; B shows a vertical cross-section, while C is a 3D rendered 
OCT image using the Amira software. 
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5.3.3 Co-culture of EC and HCT spheroids in the device 
 
Figure 5.6 Co-culture of EC and HCT spheroids in the device. This is a fluorescence image 
in which both cell types were stained by CellTracker Green. The image was taken from the 
apical side of the device. 
As a core part of the study, co-culture of EC and HCT116 spheroids in the microfluidic 
device is rather important. Because of their nature, EC hardly adhere to petri dishes as well 
as the polycarbonate membranes. EC always need a gelatin coating to promote the cell-
substrate adhesion, and a confluent monolayer of EC is desired. Therefore, EC are always 
seeded at a high concentration prior to HCT116 spheroids. After 2-3 days of culture, EC 
can reach full confluency and the spheroids are seeded with Matrigel.  Fig. 5.6 displays a 
device with HCT116 spheroids freshly seeded and stained with CellTracker Green. The 
EC layer on the membrane shows ample confluency, and the three spheroids are robust. 
The image was taken from the top of the device, in order to view the EC layer clearly. As 
the spheroids were seeded, media with different concentrations of drug, or drug-free media, 
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were infused at a low flow rate for 3 days. The behavior of both EC and spheroids is 
discussed below. 
5.3.4 EC behavior in drugs 
 
Figure 5.7 Confluent EC in the device subjected to a 3-day treatment of different 
concentrations of Paclitaxel. (I) Relative viability of EC after 3-days of exposure to 
different concentrations of Paclitaxel treatment. 
Paclitaxel of high concentration not only has negative effects on the HCT116 cells, but also 
affects EC growth. There is ample evidence that shows even low concentrations of 
paclitaxel can induce senescence of EC and change their phenotype. As shown in Fig. 5.7, 
maintaining a confluent EC monolayer in the device with drug-free media infusion 
preserves the health of most of the cells, and maintains a confluent monolayer. After 3 days 
of 1 nM, 3 nM and 10 nM Paclitaxel infusion, the confluency was maintained, and no dead 
cells were observed. The spindle-like phenotype was also preserved. However, with a 
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higher concentration of Paclitaxel infusion, the amount of spindle-like cells decreased, so 
that almost no such cells can be found in Fig. 5.7-G (3-day of 300 nM infusion). With 1 
μM drug treatment (Fig. 5.7-H), some holes and gaps as well as dead cells could be found 
on the monolayer. The cell density also decreased, as shown in Fig. 5.7- I, which indicates 
that the drug killed some of the cells and the infusion removed most of the dead cells. The 
coverage of each cell became much larger, because there was more space for each live cell. 
Such a phenotype was typical, indicating that Paclitaxel-induced senescence of EC 
reported by previous studies [193].  
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Figure 5.8 Confocal images of HCT116 spheroids subjected to 3-day 100 nM Pac 
treatment at different conditions. All the images were split to green and red channels to 
more vividly show the live and dead cells. 
5.3.5 Drug effect on HCT116 spheroids 
As mentioned before, HCT116 spheroids with an average diameter of 150 μm were seeded 
into the devices as well as to other control environments. Through 3 days of drug-free 
media treatment, both in ultra-low attachment well plates and in the EC loaded devices, 
spheroids grew vigorously with a remarkable increase in both diameter and quantity of 
dead cells on the spheroid surface, as shown in Fig. 5.8. Although, due to the hindrance of 
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Matrigel in the channel, spheroids in EC loaded devices were smaller than the ones freely 
cultured in well plate. However, through 3 days of 100 nM drug treatment, a significant 
difference was found among the well plate, EC free device and EC loaded device. The 
quantitative results of volume change and relative viability of the tumor spheroids can be 
found in Fig. 5.9 and Fig. 5.10, respectively. In the well plate, there were very limited live 
cells left and the whole structure was filled with dead cells and debris. Because most of the 
cells were dead, the 3D spherical shape of the spheroid could not be maintained and 
collapsed. In the EC-free device, there were many dead cells and very a limited amount of 
live cells after 3 days of treatment. Compared to the situation in the well plate, there were 
more live cells and less dead cells, indicating that both the membrane and Matrigel acted 
as hindrances to drug delivery. In the situation of the EC loaded device, compared to the 
other two experimental conditions, more live cells and less dead cells were observed after 
3 days of treatment. The introduction of an EC layer dramatically hindered the delivery of 
the drug from the apical channel to the tumor spheroids, especially at the beginning. Tumor 
cells are able to influence the EC monolayer permeability [194], [195], by releasing certain 
types of chemokines (such as TNF-α) which loosen the cell-cell interactions of EC. As 
some of the EC were affected by the drug (Fig. 5.7), openings on the monolayer were 
formed which allowed the drug to pass through. The 3D structure of the spheroids in both 
EC-free and EC-loaded situations were maintained, thanks to the support of Matrigel. The 
half inhibitory concentration (IC50) values of Paclitaxel for the three different 
environments are 34.8 ± 5.8 nM for well plate, 56.5 ± 13.2 nM for EC free device and 158 
± 32 nM for EC loaded device. According to the drug test results in Chapter 4, the IC50 
value of Paclitaxel for the 2D cell culture of HCT116 cells is 26.3 ± 12.5 nM, which is 
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much smaller than the one obtained by our device. Therefore, the drug screening platform 
with a combination of an EC layer, Matrigel and tumor spheroids better mimics an in vivo 
environment compared to the monolayer cell culture method and tumor spheroid cell 
culture method. Combining the drug effect on EC as shown in Fig. 5.7-I, we suggest a 
Paclitaxel concentration in blood that reaches the tumor should be in the range of 100-300 
nM.  We believe this platform has a promising potential for the anti-tumor drug screening 
industry. 
 
Figure 5.9 The volume change of HCT116 spheroids in EC loaded channels monitored 
by OCT subjected to different concentrations of Paclitaxel for up to 72 h. (* means P < 
0.05, 1-way ANOVA and Tukey post-hoc test). 
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Figure 5.10 The relative viability of HCT116 cells in EC loaded channels subjected to 
different concentrations of Paclitaxel for 72 h in well plates (A), in EC free channels (B), 
and in EC loaded channels (C). All the three figures share the same legend in the middle. 
(* means P < 0.05, 1-way ANOVA and Tukey post-hoc test). 
5.4 Conclusions 
An in vitro biomimetic anti-tumor drug screening platform was presented. The platform 
consisted of two layers with two channels and a semi-permeable membrane. An EC 
monolayer on the membrane enabled the apical channel to function as a blood vessel, which 
showed both permeability and resistance to several molecules, including drugs. 
Additionally, direct seeding of tumor spheroids more closely mimicked the in vivo nature 
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of tumors, while the Matrigel served as a scaffold for the tumor spheroids, which 
functioned as ECM. The combination of these displayed a more biomimetic 
microenvironment of a blood vessel and adjacent tissue. The drug efficacy has been 
expressed by two manners: the viability of tumor cells, which can be quantified by 
dead/live staining using confocal microscopy, and the volume change of the tumor 
spheroids, which can be quantified via OCT scanning. 
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Chapter 6:  Summary and Outlook  
The dissertation described several techniques that may significantly benefit the 
cancer early detection, cancer prognosis, and anti-tumor drug discovery. The 
research of the dissertation was mainly towards circulating tumor cells (CTC), i.e. 
how to sensitively and selectively isolate them from patient blood samples, how to 
use them as seeds to form in vitro 3D tumor models, and how to use these 3D tumor 
models for highly efficient anti-tumor drug screening. First, a CTC isolation 
platform that can be used for effective and selective capture and release of CTC by 
using wavy-herringbone structured microfluidic devices and magnetic particles was 
demonstrated, and with cooperation with a local hospital, the platform was applied 
to isolate CTCs from tumor patient blood samples. Second, another CTC isolation 
platform based on centrifugal force created by curved microfluidic channels was 
introduced, and this platform was able to isolate not only CTC, but also CTC clusters 
and WBC from RBC-lysed blood samples. With these isolated tumor cells, one of 
the applications was to create 3D tumor models that facilitated anti-tumor drug 
screening due to 3D tumor models closely mimics in vivo tumors than 2D cell 
culture. Therefore, a novel and facile method that was able to generate 3D tumor 
spheroids in large quantity with controllable size and high uniformity was then 
developed, and this technique showed promising application in anti-tumor drug 
screening in large scale and high accuracy. Last, to realize an even closer mimicking 
of in vivo tumor microenvironment, an anti-tumor drug screening microfluidic 
platform that mimicked both blood vessel and 3D in vivo tumors was shown, and a 
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well-defined anti-tumor drug was tested on the platform to show the applicability. 
A brief summary and future outlook would be made on each project. 
6.1 Wavy-HB structured microfluidic device for 
effective and selective capture and release of CTC 
We first developed a wavy-HB structured microfluidic device that was used to 
effectively and selectively capture and release CTC using immunoaffinity and 
magnetic force. Due to the pattern in the device that creates passive turbulence and 
increases the possibility of tumor cells colliding to the device wall, the device was 
rather effective on capturing tumor cells, either in pure cell suspension or in patient 
whole blood samples. The device can be potentially used for CTC sorting from 
patient blood samples, CTC concentration monitoring, therapeutic guidance, and 
further study of tumors, such as drug screening and tumor mutations. The device 
was also used for enumeration of CTCs from real tumor patient blood samples. 
However, we encountered a problem that precluded us to harvest the captured CTCs 
when dealing with real tumor patient blood samples, mainly because a lot of WBCs 
were also captured by magnetic particles (MPs), and we were not able to pick rare 
CTCs from hundreds of WBCs. A few approaches can be used to solve the problem. 
First, since the antigens we selected for CTC isolation were not expressed by WBC, 
ideally the bonding between WBC and MPs was non-specific. Study should be 
focused on why so much non-specific binding happened. Another way is to choose 
antibodies with higher specificity. The antibodies that are commercially available 
are based on IgG, so they still conceive the potential that can be recognized by WBC. 
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Therefore, aptamers may be used, because they are DNA-based and usually show 
much higher affinity and specificity than antibodies [196], [197].  
6.2 Spiral-channeled microfluidic device for CTC 
and CTCC isolation 
To effectively isolate both CTC and CTCC, we developed another microfluidic 
device that utilized the centrifugal force created by the curved channels in 
microfluidic conditions. Due to the size difference among WBC, CTC and CTCC, 
the three types of cells experienced different centrifugal forces when flowing into 
the curved channels of the microfluidic device, and the difference enabled them to 
exit from different outlets of the device. At lower flow rate, WBC could be first 
isolated, while CTC and CTCC could be isolated at higher flow rate. This device 
can be potentially used for isolation of CTC and CTCC from patient blood samples, 
CTCs concentration monitoring, therapeutic guidance, and further study of tumors, 
such as drug screening and tumor mutations. So far we have not performed isolation 
experiments with whole blood samples, which have massive RBCs. Even though the 
RBC-lysing process was deemed mild to other cells, it not only increases the 
handling complexity but also may affect fragile CTCs and CTCCs. Therefore, one 
direction of the future study should be focused on how to directly use whole blood 
in the device. Actually, since RBCs are remarkably smaller than WBCs, it is possible 
to introduce another step before the existing two steps using even lower flow rate to 
preclude RBCs from whole blood. On the other hand, as mentioned before, a plan 
was also made in our lab to perform clinic test with a local hospital for the device, 
so another direction of the future work on this project should be to demonstrate the 
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feasibility on CTC and CTCC isolation using patient samples. Besides to culture 
them to form 3D tumor models as described in Chapter 4, the comparison of protein 
expressions and DNA mutations between CTCC and CTC is important to assess the 
difference of invasiveness between the two types of cancer cells. For example, the 
proliferation marker Ki67 correlates well with invasiveness and poor outcome in 
comparison with mitotic activity index or phospho-Histone H3 staining [54]. 
6.3 Facile 3D tumor spheroid formation by 
dispase treatment and orbital-shaking 
We were able to capture and collect CTC and CTCC from blood samples. Thus with 
these isolated tumor cells, there may be a series of applications. One of them is to 
create in vitro 3D tumor models that facilitates anti-tumor drug screening due to 3D 
tumor models are closer mimicking to in vivo tumors than 2D cell culture. Therefore, 
a facile method for generation of tumor spheroids in large quantity with controllable 
size and high uniformity was then presented. Started from single tumor cells, which 
was normally the similar case when using CTCs, these cells were cultured until cell 
sheets were formed in petri dishes. The cell sheets could be detached by dispase 
treatment and assisted by the shear flow under shaking condition, tumor spheroids 
could be formed. The average size of the spheroids can be controlled by tuning the 
cell sheet culturing period and spheroid shaking period. The uniformity can be 
controlled by a set of sieves which were custom-made using stainless steel meshes. 
Since this method is based on simple petri-dish cell culturing and shaking, it is rather 
facile for forming tumor spheroids with no theoretical quantity limit. Other than 
HCT116 cells used as the model cell line, this method has been also demonstrated 
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to have feasibility on HCT116, HeLa, A431 and U87 MG tumor spheroid formation 
Drug test was performed on HCT116 tumor spheroids.  The viability, 3D structure, 
and necrosis of the spheroids are characterized. The method can be applied in anti-
cancer drug screening, in vitro tumor studies, and may be applied to primary cellular 
spheroid formation or even multi-cell type spheroid and organoid formation. So far 
the method was still in a lab level, with manual processes on tumor spheroids 
distribution into well plates and size uniformization. An idea of liquid handling 
automation, similar to the FACS, can be utilized, in which a small tube only allows 
individual spheroids passing through and small droplets can be generated at the end 
of the tube and distributed into the wells with one spheroid per droplet. And an 
automated sieve-filtering system (with its basic mechanism shown in the below 
figure) can be built to reduce the complexity on size uniformization. The system 
should allow users to select desired sieves, and the sieves can be assembled in the 
manner shown in the below figure, i.e. larger opening sieve on top of the smaller 
one, with a container underneath the two sieves to collect wastes. The samples were 
then introduced into the larger opening sieve, and after buffer washing, the set of 
sieves was disassembled, and desired spheroids could be obtained by washing the 
smaller opening sieve inversely.  
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Figure 6.1 Illustration of how to realize size filtering automation. 
6.4 Bi-layer blood vessel mimicking microfluidic 
platform for tumor drug screening 
As 3D tumor models like tumor spheroids showed advantages over 2D cell culture 
on drug screening, mimicking in vivo tumors with 3D tumor spheroids and their 
microenvironment would show even more advantages. An in vitro biomimicking 
anti-tumor drug screening platform was thus presented. The platform was consisted 
of two layers with two channels in each layer and a semi-permeable membrane in 
between. EC monolayer seeded in the apical channel and grown on the membrane 
enabled the apical channel to function as blood vessel, which showed both 
permeability and resistance to a lot of molecules, including drugs; On the other hand, 
direct seeding of tumor spheroids more closely mimicked the in vivo nature of 
tumors, while the scaffold for the tumor spheroids was Matrigel, which functioned 
as ECM. The combination of these showed a much closer mimicking the 
microenvironment of blood vessel and adjacent tissue. The drug efficacy has been 
expressed in two manners: the viability of tumor cells, which can be quantified by 
dead/live staining using confocal microscopy, and the volume change of tumor 
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spheroids, which can be quantified by OCT scanning. There are a lot of future work 
can be done using this platform. Although we demonstrated a device that bio-
mimicked the microenvironment of in vivo tumor, there are more details in the 
system that may affect drug transportation. For example, tumor cells are able to 
down regulate the permeability of EC monolayer, and the decrease of permeability 
would allow drugs go through EC monolayer and reach tumor more easily. 
Therefore, the interaction between EC and tumor spheroids should be studied. So 
far in our setup, each individual spheroid was scanned by confocal microscope and 
OCT one by one manually, and data process was also done one by one, which were 
time consuming. A system that is able to recognize, scan and analyses tumor 
spheroids automatically and integrally will dramatically improve the efficiency of 
drug screening platform.  
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Applications: 3D printing materials formulation, nano-materials preparation and 
characterization, Electrochemistry related experiments and analysis, rapid prototyping, 
microfluidic design 
AWARDS & HONORS: 
 Rossin Doctoral Fellowship, Lehigh University                                                  2015 
 Dean's Doctoral Assistantship, Lehigh University                                               2013 
 Top cited paper in 2010~2011 Biosensors and Bioelectronics                            2011 
 Outstanding Graduate (3%) Capital Normal University                                      2011 
 Special Grade Award (1%) Capital Normal University                                       2010 
PROFESSIONAL SERVICE: 
Peer reviewer for journals including: 
 Biosensors & Bioelectronics 
 Advanced Health Materials 
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 Analytica Chimica Acta 
 Electroanalysis 
 Sensors and Actuators B: Chemical 
 ACS Biomaterials Science & Engineering 
 Journal of Medical Devices 
 
 
